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1. Introduction
Hepatitis C is a disease of the liver caused by a virus identified in 1989 as the hepatitis C virus.    Hepatitis C is 
a communicable disease that is spread from person to person by contact with infected blood or body fluids.  
Intravenous drug use and receipt of unscreened blood or blood products are well established as the major risk 
factors for the acquisition of hepatitis C infection.   In comparison with HIV (Human Immunodeficiency Virus) and 
hepatitis B, the virus is much less likely to be spread through sexual contact, household contact or by mother-
to-child transmission.  The distribution of hepatitis C globally differs by time, place and person.  In Ireland those 
at risk of infection are most often socially excluded groups such as drug users, the homeless and immigrants 
from endemic countries.
Hepatitis C is most commonly an asymptomatic infection both in the acute and early chronic stages.  The 
acute stage of infection tends to go unnoticed therefore it is often difficult to establish when someone became 
infected.  Chronic infection occurs in 70-80% of adults acutely infected.  This compares to hepatitis B where 
chronic infection occurs in only 10% of acutely infected adults.  Some non-specific symptoms of chronic disease 
may occur e.g. ongoing flu-like symptoms, joint pains, abdominal pain, loss of appetite, altered bowel habit, 
mood swings and insomnia.  Complications of chronic hepatitis C include cirrhosis, liver failure and liver cancer.  
Certain factors have been identified that affect disease progression, e.g. alcohol intake, co-infection with HIV or 
hepatitis B, super-infection with hepatitis A and older age at infection.
Hepatitis C can now be treated with anti-viral agents, most commonly as a combination of two different agents.  
Treatment is not without significant side-effects.  This can affect the uptake of treatment and also adherence 
and compliance.  
In Ireland by 1994 it became apparent that individuals had become infected with hepatitis C and HIV through 
transfusion of infected blood or through administration of infected blood products in the State. In 2003, 
a working group was established by the then Eastern Regional Health Authority (ERHA) to set out key 
recommendations to enhance prevention, treatment and surveillance of hepatitis C among all infected people  
in the Eastern Region. In 2004, following on from a year long consultative process, a regional hepatitis C 
strategy document was produced.  It was developed in partnership with the statutory, voluntary and community 
sectors. Some of the recommendations of that report have been implemented, but many have not.  The report 
was never published. 
Following the establishment of the HSE (Health Service Executive) a working group was convened under the 
auspices of Social Inclusion in 2007 with the objective of developing a national strategy for hepatitis C in 
Ireland.  This document reflects the outcome of the group’s efforts.  
Implementation of this strategy will require considered, coordinated effort, utilising existing governance 
and operational structures. Ongoing monitoring and reporting of progress will be integral to this process. 
Recommended actions will be progressed on a phased, prioritised basis, with those that are deemed budget 
neutral or cost effective taking precedence in implementation.
1.1 Terms of Reference
The terms of reference for the working group are listed below.
1    To examine the 2004 ERHA report recommendations and update them as appropriate in the context of 
the establishment of the HSE.
2   To determine the current position regarding the 2004 recommendations.
3   To prioritise recommendations for 2011 and the coming three years.
4 To agree an action plan.
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1.2 Membership
A multidisciplinary working group was established with broad representation from healthcare professions, 
voluntary and statutory organisations, providers and users of services.  Three additional subgroups were created to 
focus on the areas of:
	 •	Surveillance
	 •	Education,	Prevention	and	Communication
	 •	Treatment
The area of screening for and laboratory diagnosis of hepatitis C was addressed by both the surveillance and the 
treatment subgroups.  
Full membership of the Working Group and subgroups can be found in Appendices 1 to 4.
1.3 Acknowledgements
The group would like to acknowledge the assistance of the National Cancer Registry of Ireland (NCRI), the Central 
Statistics Office (CSO), the Liver Transplant Unit in St Vincent’s University Hospital, the Irish Blood Transfusion 
Service (IBTS.
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2. EPIDEMIOLOGY OF HEPATITIS C INFECTION  
2.1 Epidemiology of Hepatitis C Infection in Ireland 
Comprehensive information about the distribution of hepatitis C infection in Ireland is limited. What information we 
have comes from routine surveillance and from special studies in high prevalence groups (such as injecting drug users 
(IDUs) and prisoners) and on people infected through the administration of contaminated blood and blood products. 
Additional prevalence data are available on blood donors. Sources of information about the burden of hepatitis C 
disease include the HSE Departments of Public Health and the Health Protection Surveillance Centre (HPSC), the 
National Virus Reference Laboratory (NVRL) the Hospital Inpatient Enquiry System (HIPE), the National Cancer 
Registry of Ireland (NCRI), mortality data from the Central Statistics Office (CSO), and liver transplantation data.
2.1.1 Information from Routine Surveillance - Notifications 2004-2010
There were 9,282 cases of hepatitis C notified in Ireland between 2004 and 2010.  The number of cases and mean age 
at notification, by sex, are shown in figure 1.
2004 2005 2006 2007 2008 2009 2010 
Male
Figure 1. Number of notifications of hepatitis C and mean age at notification, by sex, 2004-2010
Source: HPSC
The HSE-E reported 77% (n=7127) of cases notified between 2004 and 2010. The total number of notifications and 
mean annual rate per 100,000 population, for each HSE area are shown in figures 2 and 3, respectively.
East Midlands Mid West North East North West South East South West
Figure 2. Number of hepatitis C notifications by HSE-area, 2004-2010
Source HPSC
- 6 -
National Hepatitis C Strategy 2011-2014 HSE
East Midlands Mid West North East North West South East South West
Figure 3. Mean annual hepatitis C notification rates (per 100,000 population) by HSE-area, 2004-2010
Source: HPSC
Between 2004 and 2010, 64% of hepatitis C notifications were male (n=5962), 35% were female (n=3199) and sex 
was not known for the remaining cases (1%, n=121). The highest notification rates were among young to middle-
aged adults. Seventy one percent (n=6560) of cases notified between 2004 and 2010 were aged between 25 and 
44 years, and 92% (n=8529) were aged between 20 and 54 years. The mean age for male cases (35.6 years) was 
higher than that for females (34.1 years). The mean annual age and sex specific notification rates are shown in 
figure 4.
Female
Figure 4. Mean annual age and sex specific notification rates (per 100,000 population) for hepatitis C, 2004-
2010
Source: HPSC
Data on most likely risk factors  were available for 59% of cases (n=728) notified in 2010. The most common risk 
factors reported were injecting drug use (76%, n=550), being an asylum seeker/born in an endemic country (9%, 
n=63), sexual exposure (5%, n=38) and receipt of blood or blood products (3%, n=19).
Of the nineteen cases acquired through blood or blood products, seven were infected in Ireland, five were infected 
outside Ireland and country of infection was not known for seven. All cases acquired in Ireland were infected many 
years in the past, but were notified for the first time in 2010. Although information on risk factor was not available 
for 41% of notifications in 2010, the age and sex profile of these cases did not differ significantly from those for 
whom information was available.
2.1.2 Other sources of information about hepatitis C in Ireland
Little is known about the prevalence of hepatitis C infection in the general population in Ireland. However, hepatitis 
C is known to be more prevalent in certain sub-groups of the population such as IDUs and prisoners.  Hepatitis C 
may also be a concern for immigrants from high endemicity countries. Several cross-sectional studies have been 
carried out to estimate the prevalence of hepatitis C in high-risk groups. The results of these are summarised 
below. Further information is available on those who were infected in the past through the administration of 
contaminated blood and blood products. Data are also available on blood donors through the screening of this low 
risk population group.
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2.1.2.1 Injecting drug users 
Based on Irish studies cited below, the hepatitis C prevalence in the population of injecting drug users ranges from 
62 to 81%.  
One study looking at the clinical records of a random sample of opiate users attending the-then Eastern Health 
Board methadone clinics in 1997 estimated the prevalence of antibody to hepatitis C virus (anti-HCV) among those 
tested to be 79%. [1] A cross-sectional survey of the records of IDUs attending 21 specialist addiction treatment 
centres in the South-Western Area Health Board was carried out between December 2001 and January 2002. 
This study found that 66% of those sampled, and whose records showed testing for hepatitis C, were anti-HCV 
positive.  [2] A study using the records of IDUs in treatment in Dublin, who had been tested for hepatitis C between 
September 1992 and September 1997, estimated the anti-HCV prevalence in this population to be 62%.  [3] A 
retrospective cohort study among IDUs in Dublin, tested in the 1990s, estimated an overall incidence of hepatitis C 
of 66 per 100 person years.  [4]
Studies assessing hepatitis C prevalence in IDUs attending general practitioners (GPs) have also been carried 
out in the Dublin area. A 1999 cross-sectional survey of 571 patients attending 42 General Practitioners (GP) in 
the eastern region for methadone maintenance treatment reported that 73% of those whose hepatitis C status 
was known were positive. [5] A further study of GP records for 196 consenting IDUs attending for methadone 
maintenance, found that 77% had been screened for hepatitis C and that 69% of those tested were anti-HCV 
positive. [6]
2.1.2.2 Prisoners
There are high rates of hepatitis C amongst prisoners on entry to prison due to the high rate of imprisonment for 
drug related crime.  A cross-sectional survey, which included a self-completed risk factor questionnaire and testing 
of oral fluid specimens, was carried out in nine prisons in Ireland in 1998.  The response rate was 88% (n=1205), 
constituting 45% of the Irish prison population at the time. Over 40% of prisoners reported ever injecting drugs. 
Thirty-seven percent of prisoners tested were positive for antibodies to hepatitis C. Where only prisoners reporting 
injecting drug use were considered, 81.3% of those tested were positive for antibodies to hepatitis C.[7] A follow on 
study, carried out on prison entrants between April and May 1999, found 21.8% of all prisoners sampled and 71.7% 
of those who reported injecting drug use, to be positive for antibodies to hepatitis C.[8]  
Risk behaviours for hepatitis C transmission, such as unsafe injecting practices and tattooing, occur in the prison 
environment.  Confinement to prison is recognised as a specific risk factor for the sharing of drug using equipment.
[9]  Tattooing in prison has been found to be an independent risk factor for hepatitis C infection in prisoners who 
have never injected drugs.[8]   
2.1.2.3 Asylum seekers 
Although screening for hepatitis C is not part of the recommended national communicable disease screening 
programme for asylum seekers living in direct provision, it is offered in some parts of the country. A review of the 
communicable disease screening service for asylum seekers was carried out in the ERHA (now the HSE Eastern 
Region) in 2004.[10]  This service was estimated to have carried out voluntary communicable disease screening on 
35-40% of all new applicants for asylum during the years 1998-2003. Of those screened for hepatitis C between 
1999-2003, 1.5% were positive.
2.1.2.4 Hepatitis C infection through blood and blood products
Almost 1,700 people have been infected with hepatitis C through the administration of blood and blood products 
in Ireland. [11][12] These include women infected through anti-D immune globulin, people with haemophilia, 
recipients of blood transfusion and people who received treatment for renal disease. Transmission of hepatitis C 
infection through Irish blood and blood products no longer occurs as blood and blood products are now screened 
for hepatitis C.
At the request of the Consultative Council on Hepatitis C, a national research database of those infected through 
blood and blood products was established by the HPSC in conjunction with the eight designated hepatology units. 
The database records information on demographics, hepatitis C exposure, current clinical status, test results, 
hepatitis C treatment and current management. Most database participants had been infected for over 25 years by 
the end of 2008. Of those who were chronically infected, 19% had signs of serious liver disease, 14% had developed 
cirrhosis, 3% had developed hepatocellular carcinoma and 5% had died from liver related causes [13].
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2.1.2.5 Blood donor screening
The IBTS blood donor screening programme detected an anti-HCV prevalence of 0.018% (46/257358) in new blood 
donors between 1997 and 2010 (personal communication, IBTS November 2011). This very low prevalence is to be 
expected as blood donors are unpaid volunteers and individuals who are identified as having relevant risk factors 
are excluded prior to donation
2.2 Current burden of hepatitis C disease
In 2001, Kavanagh et al [14] examined the prevalence of hepatitis C and its prognostic co-factors in a group of IDUs 
attending a community based drug treatment clinic in the Eastern Region. Using their results and published data 
regarding the prevalence of opiate dependency in Ireland, the authors estimated the long term burden of hepatitis 
C related disease among IDUs in Ireland based on current figures. After 20 years of persistent viraemia, they 
estimated that there would be 1,214 cases of hepatitis C related cirrhosis nationally.  This is based on published 
estimations that 22% of those with chronic viraemia for 20 years progress to cirrhosis.   Further progression of 
these cases, again using published estimates, would result in approximately 35 cases of hepatocellular carcinoma, 
60 cases of hepatic decompensation and 50 liver related deaths per annum.
The Kavanagh paper was based on an estimated 5,519 IDUs in Ireland with chronic hepatitis C infection. However, 
it is likely that the true figure is considerably higher than this. A recently published study on the burden of hepatitis 
C infection in Ireland estimated that by the end of 2009 there were about 10,000 people in Ireland who had 
been diagnosed with hepatitis C and had chronic infection, with drug use being the most likely risk factor in 80% 
of these. Taking account of the high proportion of hepatitis C infections that remain undiagnosed, the authors 
estimated that 20,000 to 50,000 people in Ireland are chronically infected with hepatitis C virus, a population 
prevalence of 0.5-1.2%.[15]
2.2.1 Hospital In-Patient Enquiry Data
The HIPE scheme is a computer-based health information system designed to collect medical and administrative 
data regarding discharges and deaths from acute hospitals (excluding private hospitals). Each discharge record 
represents one episode of care and patients may have been admitted more than once, or to more than one 
hospital, with the same diagnosis. 
The HIPE acute hospital coverage, between 2005 and 2010, varied from 96% to almost 100%.  During this period, 
there were 2,800 discharges with a principal diagnosis of chronic viral hepatitis C. Sixty four percent were males 
and the mean annual age at admission ranged from 40 to 45 years. During the same period, there were 1,193 
discharges with a principal diagnosis of primary liver cancer. Seventy eight percent were males. The mean annual 
age at admission ranged from 60 to 65 years. (Personal communication: Economic and Social Research Institute, 
Nov 2011).  
More detailed information on hepatitis C associated healthcare utilisation is available in Appendix 5.
2.2.2 National Cancer Registry of Ireland
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. Seven hundred and three cases 
of HCC were registered with the NCRI between 1994 and 2010. The vast majority of these (79.5%) were male (figure 
5). (Personal communication: NCRI, Nov 2011).  
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Figure 5. Number of cases of hepatocellular carcinoma registered with the National Cancer Registry of Ireland 
by sex and mean age, 1994-2010
Source: NCRI
Chronic infection with hepatitis B and hepatitis C are the most important causes of HCC. A systematic review of 
all published data from nine European countries on the prevalence of chronic hepatitis B and hepatitis C infection 
among HCC cases found a prevalence of anti-HCV positivity of 34.3%, with an additional 6.5% being positive 
for both anti-HCV and hepatitis B surface antigen (HBsAg). [16] Prevalences from a smaller study in the United 
Kingdom were 27.5% and 2.5% respectively. Therefore, although NCRI data do not specify underlying cause, it is 
likely that somewhere in the region of 30% of HCC cases here are anti-HCV positive.
2.2.3 Central Statistics Office mortality data
Although no deaths were coded to hepatitis C during the period 1994-2006 (‘unspecified viral hepatitis C’), 85 
deaths were coded to ‘other specified viral hepatitis without mention of hepatic coma’. This category includes 
deaths due to acute or chronic hepatitis C, hepatitis delta, hepatitis E or other specified viral hepatitis.  Therefore, it 
is likely that most of these deaths were due to hepatitis C. There were 51 deaths coded to acute (n=20) and chronic 
hepatitis C (n=31) between 2007 and 2010 (figure 6).  Between 1994 and 2010, there were 599 deaths from primary 
liver cancer, of which 73% were male (figure 7). (Personal communication: Central Statistics Office, May 2007).
Female
Figure 6. Number of deaths due to other specified viral hepatitis without mention of hepatic coma (mostly 
hepatitis C), 1994-2006 and number of deaths due to ‘acute hepatitis C’ and ‘chronic viral hepatitis C’, 2007-
2010
Source: CSO
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Female
Figure 7. Number of deaths due to primary liver cancer, 1994-2010
Source:CSO
2.2.4 Liver transplants 
The national liver transplantation unit in St Vincent’s University Hospital, Dublin, carried out 311 liver transplants 
between 2000 and 2006. Twenty-five of these were known to be as a consequence of hepatitis C infection and a 
further seventeen were due to hepatitis C and another indication, such as alcoholic liver disease or HCC. (Personal 
communication: Liver Transplant Unit, St Vincent’s University Hospital Dublin, April 2007). 
2.3 Hepatitis C in England and Wales
Based on a variety of data sources, a recent statistical model predicted that, in 2003, there were 231,000 hepatitis 
C antibody positive individuals aged between 15 and 59 years in England and Wales. The model predicts that 31% 
of hepatitis C infections are in current IDUs, 57% in ex-IDUs and 12% are in the non-IDU population. The ratio of 
hepatitis C infected men to women is estimated to be 2.4:1 and amongst those aged 15-59 years, in England and 
Wales, the prevalence of chronic infection is predicted to be 0.53%.[17]
2.4 Hepatitis C in Europe
The annual European communicable disease epidemiological report 2010 states that the highest rate of newly 
reported hepatitis C cases in 2008 was reported by Ireland (35/100,000), followed by Iceland (29/100,000), 
Sweden (27/100,000) and Finland (22/100,000), with the overall European rate being 9/100,000. [18] However, 
they point out that, due to the nature of the disease (mainly chronic, asymptomatic infections), the relatively recent 
introduction of surveillance of hepatitis C in many countries and the differences between the surveillance systems 
used, the currently available data do not permit comparisons between countries in Europe. 
2.5 Hepatitis C Globally
The estimated global prevalence of hepatitis C is 2 – 3%, representing as many as 170 million people infected 
worldwide.[19]  Geographic and temporal variability exists with different patterns of age-specific variability. [20] 
Low prevalence countries (<1%) include the United Kingdom, Germany, Canada, and Scandinavian countries.  
Higher prevalences (1-2.5%) are reported from the USA, Japan and Italy.  The highest prevalences are reported from 
countries in Africa and Asia with the highest reported prevalence in Egypt at 22%.[21]  However epidemiological 
data from the developing world is limited.  
Age-specific patterns in the USA and Australia indicate that prevalence is highest in 30-49 year olds.  In Japan, 
China and Italy, persons over 50 years of age have the highest prevalence.  
Risk factors for acquisition of hepatitis C also differ globally.  In the developed world the main risk factor for 
new hepatitis C infections is injecting drug use whereas in the developing world the main risk factors are unsafe 
therapeutic injections and transfusion of contaminated blood.
The rising incidence of HCC in many countries is attributed to hepatitis C infection.  In Japan, where the peak 
prevalence of hepatitis C infection is in the 60-70 year age group, 90% of reported HCC is due to this infection.  
Countries where the peak prevalence of hepatitis C infection is in younger age groups, may see an increase in HCC 
as their population ages.  Australia has projected a tripling in the incidence of hepatitis C related liver failure and 
HCC by the year 2020 with an associated steep rise in health-care expenditure. [21, 22]
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Data compiled by the World Health Organization (WHO) on prevalence rates in different WHO regions are 
presented in Table 1.  However, the data shown are not necessarily accurate due to differences in the population 
groups studied, methods of data collection, limited data availability for some countries and interpretation between 
countries. [23]  Prevalence rates also date back to 1999 and an update is currently awaited from the WHO.
Globalisation over recent decades has seen a large increase in the movement of people which in turn contributes to 
the increased spread of infectious diseases.  The European Academies Science Advisory Council issued a statement 
in August 2007 on the impact of migration on infectious diseases highlighting the fact that “most migrants to 
the EU are healthy but in population terms may bear a disproportionate burden of infectious disease.”  In their 
statement they commented on the lack of comprehensive data and the scant attention paid to the public health 
implications of migration in EU policy development.[24]
Table 1: Hepatitis C estimated prevalence and number infected by WHO Region
WHO Region Total Population 
(Millions)
Hepatitis C prevalence 
Rate %
Infected Population 
(Millions)
Number-of countries 
by WHO Region where 
data are not available
Africa 602 5.3 31.9 12
Americas 785 1.7 13.1 7
Eastern 
Mediterranean
466 4.6 21.3 5
Europe 858 1.03 8.9 19
South-East Asia 1 500 2.15 32.3 3
Western Pacific 1 600 3.9 62.2 11
Total 5 811 3.1 169.7 57
Source: Weekly Epidemiological Record. N° 49, 10 December 1999, WHO
2.6 Current epidemiological knowledge about hepatitis C in Ireland - what is missing 
and how can we improve?
2.6.1 Improving the routine surveillance system
Chapter 4, section 4.3 describes the current deficiencies of the routine surveillance system for hepatitis C.  These 
deficiencies result in a lack of complete epidemiological knowledge regarding hepatitis C in Ireland and therefore 
need to be addressed.   If the recommendations described in Chapter 4, section 4.4 are implemented, the 
information from routine surveillance should improve in terms of completeness and quality.
2.6.2 A population prevalence study 
While the prevalence of hepatitis C infection has been extensively investigated in selected high risk population sub-
groups, the prevalence in the general population has not been measured previously. A scoping exercise carried out 
in 2006 proposed four different options for estimating hepatitis C prevalence in the general population in Ireland.
[25]  A proposal has now been submitted to the HSE for funding of one of these options, a study based on self-
collected oral fluid sampling on a sample of the population. The study draws on the approach that was successfully 
used to measure the prevalence of hepatitis B infection in Ireland. [26] While it has certain limitations, in terms of 
representativeness of the population and lack of information about risk factors, it is considered the most feasible 
option and the one most likely to secure a reasonable response rate. 
2.6.3 Historical trends in hepatitis C diagnoses 
Given the number of cases notified since hepatitis C became notifiable in 2004 (figure 1), and the fact that the 
majority of those ever infected will remain infected for life, it is clear that a very large number of people in this 
country are currently hepatitis C infected, many of whom were infected prior to 2004. A recent study carried out 
by the HPSC and the National Virus Reference Laboratory (NVRL) has estimated that 20,000 to 50,000 people 
in Ireland are chronically infected with hepatitis C.[15] The risk factor for hepatitis C acquisition in the majority of 
these cases is IDU. 
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A modelling exercise is required to further describe the trends in infection and identify future disease burden.  This 
exercise will then inform the planning of future service requirements. Such a project is currently being carried out 
jointly by the Health Research Board (HRB), HSE Eastern Region, HPSC and NVRL. The basis for this work is the 
use of the National Drug Treatment Reporting System (NDTRS) to create an injecting curve of treated IDUs and 
then apply hepatitis C incidence rates. Adjustments will be made to take account of hepatitis C acquired by means 
other than injecting drug use.
2.6.4  Estimating hepatitis C incidence 
There is little published information about the incidence of hepatitis C infection in Ireland. As laboratory markers 
do not distinguish acute from chronic hepatitis C infection, and most cases of acute infection are asymptomatic and 
therefore go undetected, estimation of incidence would require the follow up of a group of individuals over time to 
identify seroconversions. The feasibility of collating data nationally on routine testing of IDUs should be explored 
with a view to estimating incidence on an ongoing basis. 
2.6.5 Register of patients infected with hepatitis C virus
The ERHA obtained approval in 2004 from the office of the Data Protection Commissioner (DPC) to establish a 
register of drug users who are antibody positive for the hepatitis C virus. The aim of this register in the first instance 
is to track a patient journey from notification to referral for specialist assessment. To date only a limited amount 
of information has been captured on this database. To maximize the opportunity to plan and assess the health 
services response to this infection, a fulltime database manager with a clinical background is required. The overall 
aims of the register, articulated in 2004, are still relevant. The register should be expanded to capture all cases of 
hepatitis C nationally, other than the state-infected, who are already captured on the database described in Section 
2.1.2.4.
2.7 Summary
Information on hepatitis C infection in Ireland is improving but there are many gaps in our knowledge. Data 
are available from a variety of sources including routine surveillance and special studies. The data show a high 
prevalence of hepatitis C in certain populations, namely those infected in the past through administration of blood 
and blood products, and the ongoing larger group of IDUs. The prevalence in the general population is unknown. 
Recommendations will be made for the improvement of the routine surveillance system and for further studies and 
research to address current gaps in knowledge. These developments are necessary to enable better prevention and 
control of hepatitis C and to guide service planning for those with hepatitis C disease.
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3. Progress on 2004 Recommendations
3.1 Introduction
As previously stated, a working group came together in 2003 to produce a strategy for the prevention, treatment 
and surveillance of hepatitis C in the Eastern Region.  A wide consultation process was undertaken and the strategy 
was developed in partnership with the voluntary and statutory sectors.  A total of 48 key recommendations were 
made.
It must be emphasised again that this report was never published.  As a consequence, an implementation plan was 
never devised and therefore recommendations could not be formally introduced. 
A much needed and comprehensive strategy – underpinned by legislation - has been devised for the care of 
patients infected with hepatitis C through the administration of contaminated blood and blood products.  This 
gives these patients a statutory entitlement to a wide range of healthcare services without charge for the duration 
of their lives. 
In contrast there has been no strategic approach to the management of hepatitis C in Ireland for those infected 
or at risk of infection through other routes.   Any progress that has been made has been made at a local level and 
through the initiatives of different organisations, agencies or individuals.  
3.2 Surveillance
In 2004 problems identified with the notification system included many incomplete notifications and anecdotal 
evidence of non-notification, despite this being a legal requirement.  Efforts to improve the notification system 
have proven difficult to surmount for a variety of reasons including perceptions of data confidentiality breaches and 
threats of legal action.  The end result is that one third of hepatitis C notifications do not have patients’ names.  
Enhanced surveillance was also recommended in the 2004 report, in particular the capturing of data on risk 
groups.  This has been partially successful but in a time-consuming fashion with an inappropriate use of resources 
and not uniformly across the country.  
 A database for surveillance and progress monitoring in relation to IDUs in the Eastern Region was set up on foot 
of the 2004 report and as a result of hepatitis C infection being made a notifiable disease.  This database is still in 
development stage.  Recommendations were made in 2004 for its enhancement but have not been implemented 
due to recruitment difficulties within the HSE.  
Chapter 4, section 4.4 contains recommendations to enhance the surveillance of hepatitis C in Ireland.
3.3 Treatment access, delivery and adherence
In relation to encouragement of testing, particularly in those at moderate to high risk, the use of peer support 
networks was recommended in 2004.  This has not been carried out.  Some progress has been made in making 
relevant educational programmes available and these could be expanded.  
A recommendation was made in 2004 that existing protocols and guidelines for referral to specialist services 
should be modified to take into account the sub-culture of illicit drug use and social marginalisation.  The present 
report will recommend the establishment of an Expert Group to provide guidance on clinical issues and to develop 
standard protocols (see Chapter 7, recommendation 29).
A number of recommendations in relation to support staff in primary care were made in 2004.  Again these have 
not come to fruition and the matter is being addressed in the current report.
Greater cooperation between hepatology and infectious disease services and the Irish Prison Service (IPS) was 
recommended as many prisoners are hepatitis C positive.  The establishment of a framework that would enable 
those involved with the clinical care of prisoners to work collaboratively with staff from the hepatology or infectious 
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disease services was recommended.  Initiatives are being developed locally at two prison sites in Dublin but no 
national evidence-based framework has been put in place to date.  
The importance of the Clinical Nurse Specialist’s (CNS) role in increasing the proportion of hepatitis C positive 
individuals who could avail of treatment and maintaining patients in treatment was acknowledged in 2004 and 
there has been some progress in the recruitment of additional CNSs.  
As there is no central collation of data of persons in receipt of anti-viral treatment it is not possible to say how 
many people have been treated overall.  It is also impossible to estimate how many of those who have been 
treated are not in the state infected category.  Because of this it is difficult to set a target as to how many might 
be treated over the next number of years, but that is something that will be addressed by a needs assessment in 
recommendation 34 of this report.
3.4 Education and information
A range of recommendations pertaining to the Addiction Services was made in 2004.  These recommendations 
concerned programmes to slow down the progression from smoking to injecting heroin, expanded needle/syringe 
exchange and education to drug takers. There has been only patchy and unquantified progress in this regard.  
Recommendations from this group in relation to peer support and other education and prevention measures will 
be re-iterated in Chapter Five.  The National Advisory Committee on Drugs (NACD) and National Drugs Strategy 
Team (NDST) prepared an assessment of needle exchange provision in Ireland for the Minister for State with 
responsibility for the National Drugs Strategy in March 2008.  This assessment has not been published.  
Recommendations in relation to prevention of sexual transmission and transmission through snorting of 
cocaine were made in 2004.  However, due to the limited evidence in relation to these routes of transmission, 
recommendations will not be proposed in this current document.   Recommendations in relation to tattooing were 
made in 2004.  However, a formal approach to tattooing practices is still lacking.  Recommendations in this regard 
are repeated in this report.
3.5 Conclusion
There was considerable disappointment amongst those who contributed that subsequent to the completion of the 
2004 ERHA report it was not published.  For that reason, no implementation strategy could be agreed and many 
of the recommendations from 2004 were not implemented and are repeated in this report.  Given the experience of 
2004 it was decided to produce an action plan with time lines - these can be found in Chapter 9. 
The HSE is committed to the implementation of this plan on a phased, prioritised basis, with due regard to the 
current employment and resource constraints
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4. Surveillance
4.1 Introduction
Good quality information about hepatitis C in Ireland is needed so that appropriate actions can be taken at 
population and individual levels. At population level epidemiological information is required about the number and 
demographics of people infected, the modes of acquisition of infection, and trends in incidence and prevalence of 
infection and risk factors. It is necessary to know what genotypes are in circulation in Ireland and whether cases 
are linked, and if so how. This information is essential to guide the development of prevention and control activities 
and to plan the appropriate treatment services. Such information will also allow the evaluation of the effectiveness 
of any current or future interventions.  Individual cases may need follow-up to establish the source of infection, to 
ascertain whether any ongoing public health risk exists and to prevent further transmission of infection. 
4.2 Current situation
Hepatitis C became a notifiable disease in Ireland on 1st January 2004.[27] Prior to this, hepatitis C could be 
notified under the category “viral hepatitis, type unspecified”. Cases of hepatitis C (hepatitis C antibody, antigen 
or nucleic acid positive) must be notified by the clinician and by the identifying laboratory to the Medical Officer 
of Health (MOH), who is the Director of Public Health (DPH).  A copy of the current clinical notification form is 
available in Appendix 6 and the recommended data items to be included in laboratory notifications are listed in 
Appendix 7.  Notifications are confidential within the Department of Public Health.  On receipt of a notification 
by the Medical Officer of Health, it is checked against local infectious diseases notification databases or the 
Computerised Infectious Disease Reporting (CIDR) system to ascertain whether or not it represents a new 
notification e.g. to avoid duplicate entries for persons who have regular tests to check viral status.
If the case has been previously notified by another source, a new notification is not recorded. Follow up with the 
notifying clinician should determine that the case is receiving appropriate management with regard to hepatitis A 
and B vaccination and advice on transmission risks.  In most cases, no further public health action will be required 
other than to update records as extra information becomes available e.g. genotype.
If the case has not been previously notified, the status of the case is confirmed with the notifier.  If the case is newly 
diagnosed then further action may or may not be necessary, depending on the information provided or obtained 
from the relevant clinician.  
Public health follow-up may involve:
•			Obtaining	information	e.g.	demographic,	clinical,	risk	exposure	category	and	likely	source	of	infection	as	per	
the enhanced surveillance dataset.  
•			Determining	and	agreeing	what	further	investigation	is	required	e.g.	to	rule	out	a	healthcare	acquired	
infection.  
•			Providing	advice	if	necessary	to	the	clinician	in	relation	to	appropriate	vaccination,	clinical	referral	and	
assessment.
•			Ensuring	cases	are	advised	on	how	to	minimise	the	risk	of	transmitting	infection.
Follow up is dependent on the quality and completeness of notification data.  If details of the notifier or clinician 
are not provided on the notification form then they cannot be contacted to enable routine public health follow up 
as described above.  Contact is not ordinarily made with the patient.  The MOH sends a return of cases notified, 
without personal identifiers, to the HPSC weekly. The HPSC collates these data nationally and publishes weekly, 
quarterly and annual reports (www.hpsc.ie).  The recently agreed process for managing hepatitis C notifications in 
Departments of Public Health is available in Appendix 8.
4.3 Appraisal of the current situation 
Hepatitis C requires laboratory confirmation for diagnosis.  It is rarely diagnosed on clinical grounds, as 
presentation with acute hepatitis C is uncommon and many patients present with non-specific symptoms.  
Although the information on hepatitis C is greatly improved since it became a notifiable disease, there are 
deficiencies in the current surveillance system: 
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•			Due to the predominantly asymptomatic nature of the condition, it is likely that many infections go 
undetected.
•			Trends in the number of notified cases reflect only the numbers of people being tested, rather than the 
true incidence or prevalence of infection. The majority of people currently being tested in Ireland are 
from high-risk groups attending services where screening programmes exist or are individuals under 
investigation for liver disease.
•			Trend data are only available since 2004 when hepatitis C became notifiable for the first time.
•			Many notifications are incomplete and there is a lack of enhanced surveillance data
•			To date, little information on specific laboratory results, in particular genotype, has been provided with 
notifications.
Notification data cannot be taken as an accurate reflection of trends in incidence for the following reasons: 
•			Most acute cases of hepatitis C infection are asymptomatic and it is not possible to distinguish between 
acute and chronic cases in laboratory tests. 
•			Cases notified in a particular year may have acquired their infection many years previously. 
•			Hepatitis C became a notifiable disease for the first time in 2004 so it is likely that some of the cases 
notified since then are not newly diagnosed, rather they represent a “backlog” of previously diagnosed 
cases. 
•			With raised awareness of hepatitis C among professionals and the public in recent years, there has been 
an increase in the level of testing and consequently in the identification of already infected individuals. 
Many notifications received by the DPH do not contain full names and addresses and patients are notified by 
initials only.[28] The proportion of hepatitis C notifications containing initials rather than full names had increased 
from 12% in 2004 to 33% in 2007 (personal communication, Department of Public Health, HSE Eastern Region). 
This means that duplicate notifications cannot be identified and removed. Duplicate notifications are common for 
hepatitis C, as a case may be tested repeatedly over several years, or the case may be notified by both the clinician 
and the laboratory, or by notifiers in different regions. 
Also, without full identifiers, it is not possible for the DPH to investigate a case and take public health action where 
appropriate.  In 2007 in the Eastern Region there were 1213 hepatitis C notifications.  In 400 cases, only initials 
were given, thereby preventing further public health follow-up. 
Notification of cases of hepatitis C is a legal requirement.  However, the provision of enhanced surveillance data 
is not.  Risk factor information is rarely provided on laboratory request forms or on notifications from clinicians.  
Of the 813 notifications with full patient names received by the Eastern Region in 2007, risk factor information or 
proxies were available in 421 cases (52%).  The proxies used included attendance at a drug treatment clinic, asylum 
seeker or refugee status, intravenous drug use or imprisonment.  Use of these demographic factors as proxies for 
establishing the mode of hepatitis C acquisition has not been formally evaluated.  For the remaining 48%, contact 
must be made with the patient’s clinician to obtain additional information.  Unfortunately many notifications 
have limited information on the patient’s clinician, resulting in very time consuming and often fruitless follow-up, 
particularly in areas with large volumes of hepatitis C notifications.  Pending resolution of these deficiencies, it is a 
half-time job in the HSE Eastern Region to chase and verify enhanced surveillance data.   
The lack of complete surveillance data impacts on service planning.  The first year progress report on the Scottish 
Action Plan 2006-2008 documented that, of the 37,500 chronically infected patients in Scotland, only 20% 
had accessed specialist care and, of these, only 20% had received anti-viral treatment.[29]   As Ireland does not 
currently maintain a national register of all patients infected with hepatitis C, similar data is not available but it is 
widely held that there is a large unmet need.  A national register would facilitate: 
•			Ready access to numbers of patients who have been treated, who are on treatment, and who are awaiting 
treatment
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•			Enhanced clinical and epidemiological follow-up of patients and provision of optimal care including
o Collection of data on treatment outcomes
o Ascertainment of long-term disease outcomes and re-infection rates
o Improved “loss to follow-up” rates
A national database has been established to record data on infection acquired through blood and blood products.   
Subsequent to the 2004 ERHA report, a database for surveillance and progress monitoring in relation to IDUs was 
set up in the Eastern Region.  Although recommendations were made for the development of this database, the 
project remains in its earliest stages with lack of progress due to recruitment difficulties within the HSE.  Adequate 
funding is essential and an ethical imperative for the development and, in particular, the ongoing maintenance of a 
register.
4.4 Recommendations
Strengthening the quality and completeness of the hepatitis C notification system
Ideally, the most efficient system would be a system based on notification of cases from laboratories.  This system 
would require that all requesting clinicians enter a range of information on a laboratory request form including 
full patient identifiers (name and address), country of birth, ethnicity, likely country of acquisition of infection, any 
available relevant risk factor information, information as to whether this case is newly diagnosed or previously 
diagnosed, and clinician details.  In completing the forms, notifying clinicians should make a judgement on how 
they believe their patient acquired their infection.  This information would then be entered by laboratory personnel 
onto the lab result that is sent via CIDR to the Departments of Public Health. The report should also include 
detailed laboratory results such as RNA status and genotype.  
Unfortunately it is recognised that in a time-pressured environment this ideal system may not be feasible.  As a 
minimum it is recommended that all laboratory requests contain full patient identifiers and full clinician details 
and that samples are not processed unless this information is provided.  Laboratories should check their systems 
for previous testing on the same individual.  This information should then be transmitted with the laboratory result 
to the Departments of Public Health.
Additional relevant information is obtained from clinical notifications.  Therefore, efforts should be made to 
encourage clinicians to notify newly diagnosed hepatitis C cases and to remind them of their statutory obligation.  
Systems must be developed that facilitate them to do so. 
Recommendation 1 All laboratory requests for hepatitis C serology must contain full patient identifiers and full 
clinician details.  This information should then be transmitted by laboratories to Public Health
Organisation Responsible Clinicians
Laboratories
Recommendation 2 Encourage clinicians to notify newly diagnosed cases of hepatitis C and to provide as much 
relevant information as possible.
Organisation Responsible HSE in conjunction with practicing clinicians 
Improving surveillance of newly-diagnosed cases of hepatitis C infection 
Enhanced surveillance of hepatitis C should become the norm to enable appropriate public health follow up.   If 
recommendation 1 and 2 above are implemented this will improve the efficiency of the current system which is 
labour intensive.  Appendix 9 contains the recommended enhanced surveillance form which should be completed 
through information received from laboratories and clinicians and/or contact made by public health staff with the 
patient’s clinician.  
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Recommendation 3 Undertake enhanced surveillance of all cases of newly diagnosed hepatitis C infection 
Organisation Responsible Departments of Public Health
Recommendation 4 Establish a national register of hepatitis C infected patients (other than those referred to as 
“state-infected”) 
Organisation Responsible Departments of Public Health – led by the Department of Public Health, HSE Eastern Region
Enabling appropriate public health follow-up of newly diagnosed cases
Follow-up is imperative to prevent secondary spread and to identify the likely source of infection.  Improving the 
notification system as outlined above will enable appropriate public health follow-up of notified cases as discussed 
in section 4.2.  
Recommendation 5 Instigate appropriate public health follow-up on all cases of newly notified hepatitis C infection 
Organisation Responsible Departments of Public Health
Improving knowledge with regard to hepatitis C infection in Ireland
Chapter 2 highlighted current gaps in the knowledge regarding hepatitis C infection in Ireland.  Gaps exist with 
regard to incidence, prevalence, trends and future disease burden.  Data on the prevalence of hepatitis C in migrant 
populations should be acquired and reviewed to establish whether or not hepatitis C infection is a concern for 
ethnic minority groups in Ireland.
The proposals laid out in Chapter 2, section 2.6.2, should be carried out.  
Recommendation 6 Undertake a population prevalence study as outlined in Chapter 2, section 2.5
Organisation Responsible HPSC
Recommendation 7 Complete a modelling exercise to estimate future disease burden and aid service planning as 
outlined in Chapter 2, section 2.5
Organisation Responsible HSE - Department of Public Health (HSE East), HPSC 
HRB & NVRL
Recommendation 8 Conduct follow-up studies amongst IDUs to identify seroconverters and therefore incidence 
rates.  A national register as per recommendation 4 will facilitate this
Organisation Responsible HSE and service providers
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5. Education, Prevention and Communication
5.1 Introduction
This chapter makes a number of recommendations on initiatives to reduce new cases of infection and to reduce 
transmission of infection from those who are infected.  The recommendations are broad in nature and are aimed 
at those populations who are most at risk of infection, namely drug users, prisoners and immigrants from endemic 
countries.  This chapter also addresses communication issues around hepatitis C to improve the accuracy and 
consistency of current materials used for patients, those at risk and health care providers. 
The guiding principles that inform this work are:
1. All actions should be based on the best available evidence.
2. Harm reduction, which aims to reduce drug related harm to individuals and communities, will be 
emphasised through a wide range of policies and programmes.  These will include a wide variety of 
approaches including needle/syringe exchange programmes.  This principle is underpinned by the premise 
that harm reduction methods should be available to all.
3. A partnership approach between all levels of government, voluntary and community organisations, and 
healthcare providers is recognised as essential in the prevention and control of hepatitis C.
4. The recognition that a range of social factors such as poverty, housing, education and employment status 
influence an individual’s ability to manage their own health.
5.1.1 Collaboration 
To ensure maximum effectiveness in the delivery of an education and prevention strategy the engagement of all 
agencies in both the statutory and voluntary sectors is required.  The following, while not exhaustive, indicates the 
key agencies that should participate in this strategy. 
•		HSE
•		Specialist Treatment Services 
•		Regional and Local Drug Task Forces
•		Voluntary Agencies
•		Service User Groups 
•		Prison Services 
5.1.2 Peer education 
The involvement of individuals who are directly affected by hepatitis C or at risk of infection is desirable in the 
development and implementation of all hepatitis C related interventions.   The Third Collaborative Injection Drug 
Users Study / Drug Users Intervention Trial (CIDUS III/DUIT) designed and evaluated a six-session behavioural 
peer-education intervention.[30]   Conceptually, the peer-education intervention drew on aspects of Social Learning 
Theory, the Information, Motivation, and Behavioural skills model, peer education and leadership.  The programme 
was developed through an iterative process and through strong engagement with potential participants and local 
communities.   The programme also addressed facilitator training and quality assurance of intervention delivery.  
Participants learn the role of a peer educator and are given appropriate tools to enable them to adopt this role.  
Sessions focus on injection-related risk and sexual risk behaviour. Participants are actively prepared to encourage 
further peer education and personal risk reduction.  This model is one that could be developed and adapted for use 
in Ireland.
5.1.3 Target Populations 
Injecting drug users are at the highest risk of contracting hepatitis C.  Chapter 2, section 2.1.2.1, estimated that 
the prevalence of hepatitis C in IDUs in Ireland ranges from 62 per cent to 81 per cent.   Within a year of injection 
initiation, between 50 and 66 per cent of injectors will be infected with hepatitis C.  The 2004 report outlined the 
various risk behaviours associated with hepatitis C infection among IDUs including sharing of syringes and other 
injecting paraphernalia, backloading and unhygienic injecting.  As injecting drug use is associated with such a 
high risk of contracting hepatitis C, any strategy for the management of hepatitis C must also address the issues 
of drug use which include prevention, treatment and rehabilitation.  Hepatitis C can be just one of many health 
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concerns faced by injecting drug users, whose health is often affected by other social factors.  Intravenous drug 
users are often socially excluded, experience poor health and lack access to appropriate primary and other health 
care services.  Therefore, a more holistic approach to the health and well being of injecting drug users is required 
to improve their general health status and their health outcomes from hepatitis C infection.  This section will also 
focus on certain subgroups of the drug-using population.
5.1.3.1 Prisoners 
The high rates of hepatitis C in prison inmates pose health risks to both inmates and staff. The European 
Monitoring Centre for Drugs and Drug Addiction state that “good prison health is good public health”. [31]
A comprehensive approach to harm reduction in the prison setting should be adopted to reduce drug use, 
blood-borne virus transmission and new cases of hepatitis C, and should include:
•		Substance misuse awareness programmes
•		Supply and demand reduction programmes
•		Drug free areas
•		Prison needle exchange programmes 
•		Sterilisation equipment
•		Substitution therapies
•		Support programmes 
•		Formal links should be developed between the prison services and the addiction services to enable 
continuity of care for prisoners with drug addictions on release from custody. 
Since 1992 several countries have introduced prison-based needle exchange programmes (PNEP) as 
a result of increasing evidence of injecting drug use in prisons, the specific risks of injecting in a prison 
environment and the recognised role that prisons play in the spread of infectious diseases.   Individual 
PNEP have been evaluated and the evidence for PNEP has been systematically reviewed on several 
occasions.  One of the authors of an international review in 2004 commented “prisoners come from 
the community and most return to it.  What is done – or not done - in prisons with regard to HIV/AIDS, 
hepatitis and drug use therefore has an impact on all”. [32] This international review has been repeated as 
recently as 2006 and included site visits to different PNEP and in-depth reviews of PNEP in Switzerland, 
Germany, Spain, Moldova, Kyrgyzstan and Belarus. [33]
In summarising the findings of individual programme evaluations and systematic reviews the following 
evidence-based facts can be highlighted.  [32-40]
Prison-based Needle Exchange Programmes 
•		Are safe
•		Decrease needle-sharing practices among prisoners
•		Reduce disease transmission including HIV and hepatitis C
•		Have other positive outcomes for prisoners’ health
o Increased referral to treatment services
o Fewer overdose events
o Reduced polydrug use
•		Do not undermine safety and security 
•		Do not lead to increased drug use, injecting or initiation among prisoners
•		Do not undermine abstinence based programs
•		Have been successfully introduced in a range of prison environments 
•		Have successfully employed different methods of needle distribution to meet the needs of staff and 
prisoners in a range of prisons.
•		Protect the human rights of prisoners
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The provision of bleach and methadone has been established as an insufficient response to reducing the 
transmission of hepatitis C in the prison setting.  Prison-based needle exchange programmes have been 
recommended by medical, legal and community-based experts as well as United Nations agencies and the 
WHO.  
The Beckley Report (no 12) [41] referred to existing barriers to the introduction of harm reduction services 
in the prison setting including;
•		Possibility that the provision of services will undermine measures taken inside the prison to reduce the 
supply of drugs 
•		Denial by prison authorities that the problem of drug use and injecting exists
•		Limitations in the introduction of infection prevention services due to budget constraints or overcrowding 
•		Lack of political will 
•		Policies that prioritise zero-tolerance to drug use over the risk of infection
A variety of international instruments and declarations exist with regard to the human rights of prisoners.  
Ultimately service provision to prisoners should mirror that in the community.
5.1.3.2 Homeless
A profiling exercise, commissioned by the NACD in 2005, found that 64% (n=226) of people experiencing 
homelessness had recently used illicit drugs.[42] Methadone use was confined to the Dublin homeless and 
comprised 18% of the study group, of whom 28% were not prescribed it.  Over one-in-two current injectors 
reported sharing injecting paraphernalia in the previous four weeks (53%). Over half of problematic drug 
users were hepatitis C positive (51%) compared to 23% of the total study population. Individuals who had 
ever injected were also significantly more likely to be hepatitis C positive. Low numbers of problematic 
drug users were currently receiving treatment for hepatitis C (11%).[43]
Previous studies have also found high levels of risk behaviours – sharing of needles, injecting in public 
places and a younger age of first drug use.[44]  [45] A submission on behalf of the Safety Net Service and 
the Ana Liffey Drug Project outline a rising prevalence of hepatitis C within the homeless population from 
an estimate of 5% in 2001 to 35% in 2005. They highlight the fact that 54% of those who have hepatitis 
C and inject drugs do not always use clean needles and the fact that there are no dedicated facilities for 
homeless people who do not attend a methadone treatment centre to obtain advice regarding hepatitis C. 
[46]
Some of the issues uncovered by research to date include:
•		Services for homeless people that are under-resourced and lacking in appropriately trained staff 
•		Lack of needle exchanges and safe clean injecting environments
•		Structured treatment programmes that are inappropriate for homeless drug users 
•		Delays between initial assessment and drug treatment 
•		Difficulties accessing methadone maintenance treatment for a variety of reasons including
o lack of a permanent address,
o waiting lists, 
o harsh sanctioning for failing urinalysis 
o problems in attending daily methadone clinics 
•		Insufficient detoxification and residential places and a lack of aftercare
•		Difficulties meeting the multiple needs of homeless drug users including accommodation, retraining, 
employment and social support
5.1.3.3 Minority Ethnic Groups/ New Communities
Little is known either nationally or internationally on the use of illicit drugs by immigrants or minority 
ethnic groups (MEGs).  Merchant’s Quay Ireland (MQI) undertook qualitative research to increase 
knowledge of problematic drug use in new communities in Ireland.[47 ]  A review of the literature revealed: 
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•		Extent of drug use among new communities is not equally prevalent among all minority ethnic groups 
•		Differences may be explained by relative socioeconomic disadvantage, discrimination and by the values 
and traditions of specific ethnic groups 
•		Statistics reveal that foreign nationals including people from minority ethnic groups are often under-
represented in drug treatment statistics and over-represented in crime statistics
•		European research has mostly found that drug use among minority ethnic groups is less than that found 
among the indigenous populations 
Drug use was found to be a problem for some immigrants, with a range of drugs being used and 
administered in different ways. There were some cultural variations in types of drugs used.  The 
fieldworkers found drug users from new communities in Ireland difficult to reach as they remained hidden, 
were highly mobile and rarely associated with Irish drug users. 
The social situation of MEGs was found to constitute a risk for engagement in problematic drug use.   
Some of the main reasons given for engaging in drug use included: 
•		A means of escaping from current worries linked to the asylum process and insecure legal status 
•		A means of escaping from exclusion and isolation 
•		Experiences of post-traumatic stress disorder, war, torture and trauma 
•		Living in hostel accommodation with a lack of a family network or social support 
•		Unemployment or denial of the right to work  
•		To gain acceptance from, or to “fit in” with their Irish peers
Some of the barriers to accessing drug services identified by this research included:
•		A lack of knowledge of existing drug services and what these services have to offer, compounded by an 
inability to access information about services in their own language
•		A feeling of alienation from group work where the majority of participants are Irish
•		A fear of breach of confidentiality and concern that drug services might have connections with the 
Department of Justice or the Gardaí
•		Concern that they would encounter racism, either from the clients and/or workers
A worrying increase in the numbers of homeless people from minority ethnic groups has been noted 
recently and a significant proportion are IDUs (personal communication, Merchants Quay Ireland, May 
2008).
5.2 Current situation
A number of agencies are involved in current education, prevention and communication initiatives.  Services are 
provided by the HSE, local and regional drugs task forces and by voluntary providers.
The HSE provides education on hepatitis C prevention through a number of routes including health promotion 
services and education officers and outreach workers of the addiction services nationally.  Services are targeted 
at drug users, drugs services and community groups and are generally provided on an ad-hoc basis, based on 
requests from drugs services or communities.  They are commonly delivered through workshops facilitated by HSE 
staff.  Staff employed by the HSE in addiction and other services also provide brief educational interventions to 
those at risk of hepatitis C infection.
Both the regional and local drug task forces provide some education and prevention services in relation to hepatitis 
C.  These services are generally delivered through education workers employed by the task forces or through 
voluntary organisations funded by the task forces.  The workshop type format utilised by the HSE is again the most 
common method of delivery.  Additionally a number of task forces, notably the Ballyfermot Drugs Task Force, have 
developed a range of resources in relation to hepatitis C including a booklet and a DVD.
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A number of voluntary agencies in the addiction field provide some educational input in relation to hepatitis C.  This 
work is usually part of a wider range of services delivered to drug users.  In addition, some not-for-profit agencies 
have employed hepatitis C education workers and have produced related resources.  Community Response, based 
in Dublin south city, is an example of one such organisation.   
5.3 Appraisal of the current situation 
The majority of people at risk from or infected with hepatitis C belong to marginalised and socially excluded 
groups.  Marginalised groups can experience difficulties accessing services, they can be difficult for service 
providers to reach and have greater health and social care needs.  Often a targeted approach is required as 
opposed to a mainstream or universal approach.  
The work done to date with regard to education, prevention and communication is of value.  However, the levels of 
provision in relation to education and prevention can be described as reactive and patchy rather than strategic and 
comprehensive.  This approach to education and prevention services can lead to a situation where the information 
provided to those at risk is inconsistent and not necessarily based on the latest available evidence.  Competency-
based standards for training in health promotion do not currently exist in Ireland either for general health 
promotion or specifically in relation to training in issues relevant to injecting drug use.
The most effective way of preventing hepatitis C infection and transmission is by treating drug addiction.  The 
provision of treatment for drug addiction, including methadone substitution, is limited outside of the Eastern 
Region.  Recent figures shown in Table 2 demonstrate this.  Long waiting lists and times exist in many places where 
services are provided.  The longer a patient continues to use drugs the less likely they are to respond to treatment 
for their addiction.  Thus, it is imperative that drug addicts who wish to undergo treatment can access appropriate 
services without delay.  It is important to specifically target treatment at young and / or early injectors (within the 
first 12 months of initiation of injection drug use) as this will have the greatest impact on the prevention of hepatitis 
C. Action 39 of the National Drugs Strategy (Interim) 2009-2016 states that treatment services dealing with blood 
borne viruses, with particular emphasis on hepatitis C treatment services, be maintained and developed.[48]
Table 2:  Summary Statistics (December 2011) 
on the numbers of patients on the methadone central treatment list 
at drug clinics or GP practices per HSE area during 2011
DRUG CLINICS
Total Patients during period
HSE Dublin Mid Leinster 3126
HSE Dublin North East 2347
HSE West 239
HSE South 436
   
Prisons 1673
   
Drug Treatment Centre Board 718
GENERAL PRACTITIONERS
  Total Patients during period
HSE Dublin Mid Leinster 2251
HSE Dublin North East 1372
HSE West 222
HSE South 92
Treating and preventing drug addiction can be challenging and some people will continue to inject drugs.  
Therefore, harm-reduction materials must be provided for those who continue to use drugs, including clean needles 
and syringes.  Other paraphernalia such as smoking foils should also be provided as those who remain addicted 
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could potentially transition from injecting back to smoking heroin, thus reducing the risk of hepatitis C infection and 
transmission.  
Inadequate provision of harm-reduction materials contributes to the spread of blood borne disease.  Provision of 
safe injecting equipment through needle/syringe exchange programmes has been shown to reduce the frequency 
of unsafe injecting.[49]   Programmes providing harm-reduction materials can also provide a cleaner more hygienic 
injecting environment for some IDUs e.g. homeless drug users.  They also provide a point of contact with the health 
services and therefore opportunities exist for referral to addiction services, referral to social welfare services and 
provision of advice and education re safe injecting practices.  
Recommendations 62 and 63 of the National Drug Strategy (2001) called for a review of existing needle-exchange 
facilities with a view to ensuring access for all injecting drug users to sterile injecting equipment and the setting up 
of a community pharmacy needle and syringe exchange programme was identified as a priority. [50] 
Key points made in a review of harm reduction approaches included:
•		Needle-exchange	programmes	(NEPs),	which	provide	clean	paraphernalia,	advice	and	education	to	drug	users,	
are recognised internationally as a key component of harm reduction strategies
•		Pharmacy-based	NEPs	are	cost	effective	and	provide	an	extensive	network	of	contacts	for	drug	users,	not	all	of	
whom take part in formal programmes
•		NEPs	have	been	positively	associated	with	a	decrease	in	the	transmission	of	HIV
This review echoed the recommendations of the National Drug Strategy (2001).
Difficulties can arise when trying to minimise harm amongst drug users under the age of 16.  It is not permissible 
by law to provide those under 16 with clean injecting equipment without parental consent.  This poses a barrier to 
adequate hepatitis C preventative efforts in those under 16.
Knowledge with regard to hepatitis C infection, and in particular treatment, has increased greatly in the last 
decade.  Benefits of treatment now outweigh side effects and the threshold for treatment has changed in some 
services. Individuals who were tested in the past but not offered treatment for varying reasons e.g. treatment was 
not available, treatment criteria were not met, chaotic lifestyles and severe drug addiction, may now be able to 
avail of treatment in some services.  They should be informed of the possibility that their infection could now be 
treated. A national awareness campaign should be undertaken to advise such patients to visit their GP or the drug 
treatment services, if previously known to them, for assessment.  Services must be adequately resourced to enable 
an appropriate response to such a campaign and the improved surveillance as recommended in Chapter 4 and the 
needs assessment as recommended in Chapter 7 will help to inform service requirements.
Communication and information
Numerous materials exist that are used to educate service providers, drug users and patients infected with hepatitis 
C regarding risk factors, risk prevention, symptoms and signs, and management of hepatitis C.  Inconsistencies in 
the information provided are likely as no nationally standardised approach has been adopted to date.  Up-to-date, 
accurate and consistent information needs to be provided to all affected by hepatitis C including patients, drug users 
and service providers.  Domains of information required for the different groups are listed in Tables 3, 4 and 5.
Table 3:  Hepatitis C information 
needs of service providers
SERVICE PROVIDERS
Prevalence and incidence
Transmission risks
Screening / diagnostic tests
Treatment options
Treatment benefits and risks
Referral guidelines
Table 5: Hepatitis C information 
needs of patients diagnosed with 
hepatitis C
PATIENTS DIAGNOSED
Disease characteristics
Prognosis
Treatment options
Treatment benefits and risks
Complementary therapies
Accessing services
Table 4: Hepatitis C information 
needs of drug users  
DRUG USERS
Risk factors
Eliminating / Minimising risk
Accessing preventative services
Disease characteristics
Testing for hepatitis C
Treatment benefits and risks
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Improved surveillance of hepatitis C as outlined in chapter 4 will aid in the provision of accurate and updated 
advice. Culturally and linguistically appropriate and literacy-proofed material should be used.   Individuals for 
whom English is not their first language will require access to appropriately qualified interpreters.  Alternative 
methods of disseminating and providing information and education to different target groups should be evaluated 
and the most effective approach used.   The accuracy of scientific information should be agreed and presented in 
an appropriate format.  
Provision of information will increase awareness of hepatitis C and will have a subsequent impact on service 
demand.  This must be anticipated and capacity issues addressed.  This will be of particular relevance when 
contacting individuals who tested positive in the past and did not or could not avail of treatment.
National standards in health promotion qualifications and training are currently being devised.  The health 
promotion aspects of preventing drug use and working with drug users should be incorporated within these 
standards and should be evidence-based.  National standards in health promotion qualifications / training 
with regard to working with drug users will enable the development of improved informational and educational 
materials.  
UISCE – UNION FOR IMPROVED SERVICES, COMMUNICATION AND EDUCATION
UISCE is aware of a disparity between the numbers infected with hepatitis C, and those receiving 
treatment, having encountered many IDUs who have tested positive for hepatitis C, but are 
unaware of treatment options. Studies indicate that there can be an excellent response to 
treatment among IDUs in the long term.
There is a need for information to be directed towards current, former and potential IDUs, 
delivered in imaginative ways, utilising peer workers. Such information should address both 
treatment and prevention. There are still some misconceptions about treatment, and IDUs need 
to be updated on all treatment options and criteria for treatment before they are tested. In 
terms of prevention, switching from intravenous use to smoking heroin and cocaine should be 
considered. Needle exchange services need to be expanded to cover prisons, out-of-hours and 
weekends.
Treatment should be available to all those infected with hepatitis C regardless of how the disease 
is acquired. It is also important that hepatitis C services engage with all those who are infected, 
whether they are suitable for treatment or not.
Where there are issues of stability preventing treatment, it is important that a care plan is 
developed through a co-operative approach between the appropriate agencies. Where this 
involves voluntary agencies, models of best practice regarding inter-agency work should be 
followed. Prospective patients should be very clear about what is required of them in order to 
avail of treatment.  A significant amount of work is involved in the “pre-treatment” stage to 
prepare patients for treatment and to improve/maintain their general health, such as advice on 
diet, alternative therapies and provision of information on other specialised agencies. 
Those in prison require the full range of relevant health promotion and treatment services. Not 
only should these include diagnostic and treatment services, but also access to sterile injecting 
equipment.  A prison sentence can be used opportunistically to initiate treatment, and every 
effort should be made to identify and encourage suitable prisoners to avail of treatment.
UISCE appreciates being invited to contribute to this new strategy and hopes that sufficient 
resources are made available to ensure its successful implementation.
Vignette 1:  UISCE – Union for improved services, communication and education
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5.4 Recommendations
Prevention of infection through initiatives targeting injecting drug use
There are five key strategies to adopt in targeting ongoing illicit and injecting drug use.
1. Treat existing drug addiction
2. Prevent transition from smoking heroin to injecting
3. Discourage established injectors from initiating others into injecting
4. Increase the provision of harm-reduction materials
5. Improve the deficit in knowledge among staff and those who are injecting in terms of understanding the 
risks 
It is recommended that a co-operative approach to these issues should be taken by the HSE as there are significant 
opportunities for synergies between the work of the voluntary and statutory sectors.
Treat existing drug addiction
Recommendation 9 •		Increase	the	number	of	drug	treatment	facilities	including	detoxification	units,	methadone	
clinics, treatment for addictions other than intravenous heroin use etc, particularly outside 
of the Eastern Region
•		Reduce	existing	waiting	lists	for	treatment
•		Reduce	delays	between	assessment	and	treatment
•		Target	young	and	newly	initiated	drug	users
•		Provide	flexible	holistic	services	that	can	meet	the	needs	of	all	drug	users	including	
homeless drug users and drug users from new communities
•		Develop	prison-based	drug	addiction	treatment	programmes	that	are	linked	with	
community-based programmes for when prisoners are released
•		Provide	after-care	and	rehabilitation	services	to	prevent	relapse
Organisation Responsible  HSE 
 Existing organisations
Prevent transition from smoking heroin to injecting
Recommendation 10 •		Develop	interventions	to	delay	/	prevent	transition	from	smoking	to	injecting,	including	
training for staff in motivational interview techniques and brief interventions.   
•		Treat	drug	addiction	in	those	who	have	become	dependent	but	are	not	yet	injecting,	in	line	
with national performance indicators as outlined in the National Drugs Strategy.
Organisation Responsible HSE 
Discourage established injectors from initiating others into injecting
Recommendation 11 Work with established injectors to discourage them from initiating others into injecting 
through peer education
Organisation Responsible HSE 
Voluntary service providers
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Improve provision of harm-reduction materials
Recommendation 12 •		Ensure	all	drug	users	have	access	to	harm-reduction	materials	regardless	of	location
•		Expand	the	current	provision	of	harm-reduction	materials,	particularly	outside	of	the	
Eastern Region, both in terms of geographical coverage and time
•		Eliminate	the	policy	of	“one	for	one”	needle/syringe	exchange
•		Encourage	collaborative	links	with	local	Gardai	around	centres	for	provision	of	harm-
reduction materials
Organisation 
Responsible 
HSE 
Voluntary service providers
Recommendation 13 Promote provision of harm-reduction materials within the pharmacy setting
Organisation Responsible Department of Health (DoH) 
HSE
Targeted strategies for socially excluded groups
A proposal has been put forward by the Ana Liffey Drug Project and Safetynet to provide an innovative and 
necessary response to hepatitis C issues among the problem drug using homeless population in Dublin - Dublin 
Area Homeless Hepatitis C Project.  The services offered would include hepatitis screening, harm reduction 
education and ongoing support for the management of blood borne infectious diseases including hepatitis C.  
Active targeting and outreach work would be employed to facilitate inclusion.  The project should also include 
evaluation, review and research. 
Recommendation 14 Pilot and evaluate the Dublin Area Homeless Hepatitis C Project 
Organisation 
Responsible 
Safetynet
Ana Liffey Drug Project
Mountjoy Street Family Practice
HSE 
Recommendation 15 Implement recommendations from the MQI report entitled “Drug Use Among New 
Communities: an exploratory study” on a national basis including:-
•		Engage	hard-to-reach	drug	users,	including	those	from	EMGs,	through	drugs	outreach	
teams
•		Promote	community	engagement	in	the	design	and	delivery	of	services
•		Recruit	staff	from	EMGs	into	the	drug	services	
•		Provide	anti-racist	and	cultural	competency	training	to	staff	in	the	drug	services	as	part	of	a	
wider initiative for all health and social care providers
•		Provide	culturally-specific	drug	awareness	training	to	different	cultural	groups	as	indicated
Organisation Responsible HSE - Drug treatment services
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Guidelines governing tattooing, permanent make up or body piercing 
There are currently no guidelines or regulations governing tattooing, permanent make up (PMU) or body piercing in 
Ireland.   Draft guidelines have been sent to the DoH that address 
•		Infection risks associated with body piercing, tattooing and permanent make-up
•		Best practice standards with regard to 
o premises, procedures and treatments 
o client information and consent 
o equipment, cleaning and decontamination 
o waste management 
The issue of tattooing in prisons should also be addressed.  A study in Ireland in 1999, of 607 prison entrants, 
identified tattooing in prison as the only independent risk factor for a positive antibody test in prisoners who had 
never injected drugs.[8]  
Recommendation 16 •		The	DoH	to	approve	both	the	draft “Best Practice Guidelines for Body Piercing” and draft 
“Best Practice Guidelines for Tattooing and Permanent Make Up” and issue to practitioners 
nationwide.
•		The	DoH	to	appoint	an	agency	or	representative	to	monitor	the	implementation	of	these	
guidelines following roll-out to practitioners nationwide.  
•		Regular	inspections,	in	the	interests	of	public	health	and	health	and	safety	in	the	
workplace, to ensure adherence to standard precautions.
•		Develop	an	information	leaflet	to	inform	the	public	of	the	health	risks	involved	in	body	
piercing, tattooing and PMU and to highlight the dangers inherent in unprofessional and/or 
self-administered tattoos and/or piercing.
Organisation Responsible DoH 
Communication and information
Up-to-date, accurate and consistent information needs to be provided to all affected by hepatitis C.
Recommendation 17 Review existing informational and educational material that is in current use with a view to 
proofing (culturally, linguistically and literacy), standardising and  improving the quality of 
information 
Organisation Responsible HSE
Recommendation 18 Facilitate access to a standardised accredited interpreting service for individuals who do not 
have English as their first language  
Organisation Responsible HSE – Social Inclusion Directorate
Recommendation 19 Provide clear, consistent and updated advice on the transmission risks of hepatitis C to those 
involved in the diagnosis and management of hepatitis C patients in the community.
Organisation Responsible HSE - Departments of Public Health, HPSC
Recommendation 20 Include competency based training modules on harm reduction for all those working with 
drug users in a community setting that are guided by national standards in health promotion 
Organisation Responsible HSE via Social Inclusion Governance Group
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Recommendation 21 •		Employ	staff	trained	to	an	appropriate	standard	in	all	services	engaged	in	health	promotion	
to prevent hepatitis C infection.  
•		Develop	minimum	standards	of	education	for	outreach	and	other	staff	who	are	in	direct	
contact with IDUs 
•		Standardise	recruitment	and	training	for	peer	educators	that	is	evidence-based	and	
continuously evaluated.  A model similar to that used by the CIDUS III/DUIT Study (see 
section 5.1.2) could be developed.
•		Increase	learning	from	peer	education	models	already	in	place	(e.g.	UISCE,	Community	
Response)
Organisation Responsible HSE 
Voluntary service providers
Recommendation 22 Plan and implement a campaign to raise awareness amongst those who may previously have 
been diagnosed with hepatitis C or who may have been at risk of infection in order to redirect 
them to medical services if this is what they choose
Organisation Responsible HSE 
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6.  Screening and Laboratory Testing for Hepatitis C Virus 
Infection
6.1 Introduction
Screening can be defined as “a public health service in which members of a defined population, who do not 
necessarily perceive they are at risk of, or are already affected by, a disease or its complications, are asked a question or 
offered a test to identify those individuals who are more likely to be helped than harmed by further tests or treatment to 
reduce the risk of disease or its complications.”[51]
The objective of screening for the early detection of disease is to benefit the individual and the greater population 
by reducing morbidity and mortality from the disease.  Screening can be opportunistic or as part of a screening 
programme, which can be universal or targeted.  Programmes are formally organised with a defined population 
to be screened and all activities along the screening pathway must be planned, co-coordinated, monitored 
and evaluated with the application of rigorous quality assurance.  Programmes must ensure that the benefit of 
screening outweighs any possible harm and must demonstrate a reduction in mortality or morbidity.
There have been many studies on the cost effectiveness of hepatitis C screening programmes most of which fail 
to demonstrate a benefit when measured in cost per Quality-Adjusted Life Year (QALY).  Selective screening of 
high-risk populations (with high levels of acceptance of screening and adherence to treatment) is more likely to be 
cost effective than universal screening. The cost of laboratory testing is a significant contributor to the high cost of 
hepatitis C screening programmes.
In the 2004 Regional Hepatitis C Strategy, guidance was given on those who should be proactively tested for 
hepatitis C and those who should be considered for testing (see Table 6). Haemodialysis patients and blood, blood 
product, tissue and organ donors were considered high priority for testing to protect both staff and patients during 
healthcare related interventions.  
Many patients are tested for hepatitis C infection in the community setting.  Viral ribonucleic acid (RNA) 
measurement can be logistically difficult in the community as fresh blood samples need to reach the appropriate 
laboratory within 6 hours of phlebotomy.  This is mostly a problem in ‘out of hours’ services and in many GP 
practices.  Due to these constraints hepatitis C RNA testing cannot currently be recommended in community 
settings.  Unless addressed this will result in increased pressure on overloaded secondary services who are 
currently best placed, but inappropriately so, to perform hepatitis C RNA testing. Introduction of the hepatitis 
C antigen test may go some way to alleviate this bottleneck in RNA testing as the same constraints in sample 
preparation do not apply thereby simplifying logistical problems. 
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Table 6: Who should be tested for hepatitis C virus infection
Patients who should proactively be offered testing for hepatitis C
•		Haemodialysis	patients
•		Blood,	blood	product,	tissue	and	organ	donors
•		Persons	who	have	had	an	anti-D	or	a	blood	product	transfusion	prior	to	1991
•		All	drug	users,	especially	those	who	have	injected	drugs	or	shared	‘works’,	including	prisoners
•		Babies	born	to	hepatitis	C	infected	mothers
•		Immigrants	from	countries	of	high	endemicity	for	hepatitis	C	infection
•		Persons,	including	healthcare	workers,	who	have	had	potential	percutaneous	or	mucous	membrane	exposure	to	hepatitis	
C
•		HIV	or	hepatitis	B	infected	patients
•		Those	with	unexplained	persistently	raised	serum	transaminases
Patients for whom hepatitis C testing should be considered
•		Sexual	partners	of	people	who	have	hepatitis	C	(low	risk)
•		Men	who	have	sex	with	men	who	present	for	sexually	transmitted	disease	screening	(low	risk)
•		Those	with	tattoos	or	body	piercing
•		As	part	of	antenatal	screening
Source – 2004 ERHA Regional Hepatitis C Strategy
6.2 Laboratory Testing 
6.2.1 Laboratory Methods for Hepatitis C Testing
Screening for hepatitis C involves testing blood for the presence of antibodies to the hepatitis C virus or more 
recently the detection of hepatitis C antigen in serum. The initial screening test used is an enzyme immunoassay 
(EIA) test.  Infection is confirmed by a second alternative antibody test, commonly a line immunoassay. Antibody 
and antigen testing can identify acute, chronic or resolved infection.  Chronic infection must be confirmed by further 
testing for the presence of  viral antigen or nucleic acid on a second sample taken 6 months after the first.    
Molecular investigation consists of the detection of hepatitis C RNA, hepatitis C genotype testing and estimation 
of viral load.  At least six different genotypes of the hepatitis C virus exist and therefore genotyping is carried out in 
cases of confirmed chronic infection.  Genotyping is relevant as different genotypes respond differently to anti-viral 
treatment.  Genotyping can also be used when trying to establish the source of infection. 
Success of hepatitis C treatment is defined as testing negative for hepatitis C RNA six months after cessation 
of therapy, termed a sustained virological response (SVR). The rate of response to therapy is also an important 
predictor of sustained response with a rapid decline in viral load being a strong predictor of treatment success.
A more technical description of laboratory methods can be found in Appendix 10. 
6.2.2 Availability of Serological Investigation of Hepatitis C in Ireland
The current situation regarding serological investigation for hepatitis C infection in Ireland was established in 2007 
through a telephone survey, carried out by the HPSC, of 66 diagnostic laboratories (Table 7). 
Of the 66 laboratories, 18 perform serological diagnostic tests for hepatitis C.  The rest do not undertake any 
hepatitis C diagnostic testing.  
Of the 18 laboratories who do test, the NVRL performs the most assays including serological tests (EIA, line 
immunoassay, antigen and antigen-antibody combination assay) and molecular investigations (hepatitis C RNA 
viral load and genotyping). 
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Table 7:  Results of a telephone survey to determine what serological tests for 
hepatitis C are carried out in 66 diagnostic laboratories in Ireland (HPSC 2007)*
Serological tests done No. of labs
None 48
EIA testing only 15
EIA + line immunoassay testing 2
EIA, line immunoassay, Ag/Ab combination 
assay and molecular investigations
1   
* molecular investigations are also done in a research laboratory in UCC
Of the remaining 17:
•		Two	laboratories	perform	initial	antibody	screening	tests	(i.e.	EIA)	and	confirm	positive	EIA	by	line	
immunoassay. They then refer anti-HCV positive samples to the NVRL for molecular investigation. 
•		One	laboratory	performs	initial	antibody	screening	tests	(i.e.	EIA)	and	refers	reactive	samples	to	the	NVRL	for	
confirmation of results (i.e. line immunoassay) and to the virology research laboratory at University College 
Cork (UCC) for molecular investigation. 
•		Fourteen	laboratories	perform	initial	antibody	screening	tests	(i.e.	EIA)	but	refer	reactive	samples	to	the	NVRL	
for confirmation and further molecular analysis if required. 
6.3 Appraisal of the Current Situation   
6.3.1 Persons who have had an anti-D or a blood product transfusion prior to 1991
It is estimated that nearly 1,700 people have been infected with hepatitis C through the administration of 
contaminated blood and blood products.   The routine screening of blood for hepatitis C antibody began in 1991.  
A targeted lookback programme began in January 1995 to identify recipients of potentially infected blood prior 
to 1991.  A more generalised optional screening programme was instigated in September 1995 to reach those 
individuals who were not identified through the lookback exercise.    With regard to women infected through the 
administration of contaminated anti-D, a national hepatitis C screening programme was initiated by the IBTS in 
1994.  
6.3.2 All drug users, especially those who have injected drugs or shared ‘works’
Drug users who attend drug addiction services are screened on first presentation for blood borne viral infection, 
including hepatitis C.  Different protocols are employed with regard to the frequency of hepatitis C screening 
thereafter in those who are either negative or antibody positive but hepatitis C RNA negative.  Individuals who are 
repeatedly exposed to risk factors will require ongoing screening.
Not all IDUs will present for addiction treatment and a significant proportion will continue to inject.  Of these 
a certain number will attend services providing harm-reduction materials, providing a point of contact with the 
health services and an opportunity to screen for blood borne viruses including hepatitis C.
6.3.2.1 Prison population 
The Irish Prison Service healthcare standards (2006)  state in their clinical policy on screening for infectious 
or communicable diseases that “in view of the long-standing association between I/V drug use, infection with 
communicable diseases (in particular hepatitis B, C, and HIV), and criminality with the risk of incarceration it 
has been long-standing healthcare policy and practice to regard the prison population as being at high risk for 
such conditions. In this context it is recommended that all persons entering prison who volunteer a background 
history with risk factors for any infectious disease should be offered any available screening for that condition.”[51] 
Many prisoners have been tested in the past and details and results of previous tests should be sought to avoid 
duplication and unnecessary testing.
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The health care standards also outline the expected standard of care in relation to hepatitis C.[52]  Prisoners 
should be provided with
1. General health information in relation to hepatitis C.
2. Advice and testing for hepatitis C where clinically indicated.
3. Referral to appropriate specialist services.
4. Treatment and support for those infected with hepatitis C.
These standards with regard to hepatitis C screening and care in the prison population need to be fully 
implemented.  Some progress in this area has been made with the recent appointment of addiction nurses and the 
establishment of inreach services in two prisons.  
6.3.2.2 Women Working in Prostitution
The Women’s Health Project for Women Working in Prostitution is a service provided by the HSE and offers free 
screening for blood borne viruses and other sexually transmitted infections.  The service is based in Dublin and 
covers the former East Coast, Northern and South Western Areas.  A review of 150 new attendances at the clinic 
between 1991 and mid 1997 found that eight per cent reported current intravenous drug use.   Sixty-six per cent 
overall were tested for antibody to hepatitis C and 8.1% were positive.   Injecting drug users were significantly more 
likely to test positive (83.3% Vs 3.2%).[53]
6.3.2.3 Immigrants from countries of high endemicity for hepatitis C infection
Some asylum seekers have contracted infection through injecting drug use but many come from endemic countries 
in the developing world and acquired infection through re-use of needles and syringes in impoverished healthcare 
settings.  Hepatitis C screening is not officially recommended as part of the screening programme but is carried out 
routinely in all Dublin reception centres and in some other accommodation centres around the country.  The degree 
of testing carried out depends on the ability to transport specimens to the laboratory in a timely fashion.   Some 
difficulties exist, particularly in more rural areas, with transport of PCR specimens within the required timeframe 
and therefore patients are referred to specialist services on the basis of positive antibody results.
Currently only immigrants who apply for asylum and who reside in direct provision accommodation are offered 
hepatitis C screening in some areas around the country.  The number of asylum applications has decreased in 
recent years and asylum was only granted in 7% of finalised asylum cases between 2001 and 2010. Far greater 
numbers enter the country on work permits, work visas and student visas. Many of these immigrants are from 
endemic countries.  With the enlargement of the EU many more people have immigrated to Ireland from the new 
member states where hepatitis C infection is more prevalent.  
Information on asylum applications and work permits are presented in Table 8 and Table 9.  Data on asylum 
applications were provided by the Office of the Refugee Applications Commissioner and data on work permits 
were provided by the Department of Jobs, Enterprise and Innovation. The information is categorised according 
to the hepatitis C prevalence in the country of origin.  The majority of immigrants come from countries where the 
prevalence is greater than 2%.  
Table 8: Number of asylum applications between 2001  and 2010 by hepatitis C prevalence in country of 
applicant
Hepatitis C prevalence (%)[19] Number of asylum applications %
<1% 1031 1.8
1-1.9% 2858 5.1
2-2.9% 21439 38.5
>2.9% 29135 52.3
Unknown 1278 2.3
Total 55741 100
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Table 9: Number of new work permits issued in Ireland between 2000 and 2010 by hepatitis C prevalence in 
country of applicant
Hepatitis C prevalence (%)[19] Number of new work permits issued %
<1% 443 0.4
1-1.9% 29222 23.2
2-2.9% 90928 72.2
>2.9% 5049 4
Unknown 240 0.2
Total 125882 100
An expert group is currently being established under the auspices of the HPSC to review guidelines for the 
infectious disease screening of asylum seekers and to extend the guidelines to include all new entrants to the Irish 
healthcare system.
6.3.3 Persons including healthcare workers who have had percutaneous or mucous membrane exposures to 
potentially hepatitis C infected blood
A document on the prevention of transmission of blood-borne diseases in the health-care setting was published 
by the DoHC in 2005.[54]  This document does not specifically address the issue of post-exposure investigation 
but gives clear guidance on reducing the risks of transmission in health-care settings from infected patients, staff, 
and devices or instrumentation.  All health-care employers should have formal written procedures in place in the 
event of occupational blood exposures (e.g. needle-stick injuries) to potentially blood borne virus infected material.   
Expert advice should be easily and promptly available e.g. through emergency departments, via a ‘hotline’ or 
through direct access to occupational health or infectious disease services.   Lookback policies must exist in the 
event of patient exposure to potential hepatitis C infection. 
The infectivity of health-care workers who are hepatitis C RNA positive is uncertain.  With regard to screening of 
healthcare workers, these guidelines recommend that staff who perform exposure-prone procedures (EPP) must 
be tested for antibodies to hepatitis C virus and, if positive, subsequently tested for hepatitis C virus RNA.   The 
guidelines also contain recommendations for screening of patients pre-dialysis.   
6.3.4 Antenatal screening
The prevalence of hepatitis C in antenatal populations is in the region of one per cent or less.  
One of the primary aims of universal antenatal testing for infections is to intervene if possible and prevent mother-
to-child transmission of infection and adverse outcomes for the child.  Antenatal screening for maternal HIV 
infection is a clear example of the application of this principle.  In the case of antenatal screening for hepatitis 
C, there are no current evidence-based interventions that reduce transmission from mother-to-child.  To date 
insufficient evidence exists to recommend specific obstetric intervention or to recommend against breastfeeding.   
No critical hepatitis C RNA titre in the mother has been established which is associated with increased risk of 
vertical transmission.  In addition, treatment of hepatitis C in pregnancy is contra-indicated.
Early treatment in children is problematic due to difficulties with establishing definitive HCV status  and a lack 
of suitable treatment for children under three.  The natural history of the disease in children, particularly those 
infected through vertical transmission, is unclear.  Concerns exist with regard to the long term effects of treatment 
in children.  The benefits of treating asymptomatic children have not been clearly demonstrated to date.  
For these reasons universal antenatal testing for hepatitis C is not currently recommended.  Targeted screening 
should be carried out for women at high risk, with declared risk factors.  However, some maternity units carry out 
universal testing.
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6.3.5 Babies born to hepatitis C infected mothers
Babies born to hepatitis C infected mothers should be screened for hepatitis C infection.  Vertical transmission rates 
are in the order of 5%, with higher rates reported where mothers are co-infected with HIV.  Diagnosis of hepatitis C 
infection soon after birth can be difficult and prolonged follow-up is necessary to make a definitive diagnosis.
Some parents of infants who are referred for further assessment and treatment for hepatitis C require additional 
support to ensure they bring their child to clinic appointments.  Currently, clinical nurse specialists in paediatric 
clinics endeavour to ensure that appointments are kept.
6.4 Recommendations
Recommendation 23 •		Provide	ready	access	for	GPs	and	other	community	healthcare	providers	to	
diagnostic facilities. 
•		Optimise	transport	of	samples	to	the	laboratories	by	the	provision	of	a	responsive	
courier service.  
Organisation
Responsible
HSE – Access to Diagnostics (GP/Community) Initiative Governing Group
Recommendation 24 •		The	IPS	to	implement	the	recommendations	in	parts	one	and	two	of	the	report	
“Hepatitis B, Hepatitis C and HIV in Irish Prisoners: Prevalence and Risk” with 
regard to infectious disease control.
•		Provide	every	prisoner	on	committal	with	a	hepatitis	C	risk	assessment,	including	
details of previous virological tests, and offer screening for blood-borne viruses, 
including hepatitis C, if required.
•		Monitor	uptake	of	testing	
•		Ensure	appropriate	follow-up	is	provided
Organisation 
Responsible 
Irish Prison Service
Recommendation 25 The NVRL, on request, to release results of previous tests to medical practitioners 
with the patient’s consent
Organisation 
Responsible 
NVRL
Recommendation 26 Establish guidelines with regard to hepatitis C screening of individuals from endemic 
countries / new entrants to the Irish healthcare system.
Organisation 
Responsible 
HPSC Scientific Advisory Committee 
Recommendation 27 •		Continue	targeted	antenatal	screening	for	those	with	risk	factors	for	hepatitis	C	
infection
•		Regular	review	of	the	evidence	with	regard	to	universal	antenatal	screening	
Organisation 
Responsible 
Maternity Hospitals
General Practitioners
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Recommendation 28 Offer and promote screening for hepatitis C and other blood-borne diseases to 
those who attend services such as Needle-Exchange Programmes and other harm-
reduction services
Organisation 
Responsible 
HSE Drug services
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7. Treatment
7.1 Introduction
The 2004 strategy document identified challenges with regard to treatment access, delivery and adherence and 
made recommendations on improving assessment and treatment.   Short, medium and long term goals with 
regard to treating those with hepatitis C were outlined.  
This current chapter on treatment and support has been prepared to update the recommendations in the previous 
2004 report.  The aims are:
•		To discuss recent advances in treatment
•		To identify current treatment initiatives 
•		To make recommendations, applicable to the Irish context, on the future development of treatment and 
support services
Throughout this chapter, vignettes are provided to illustrate some of the different models of care that are in 
operation.
7.2 Drug Treatments
7.2.1 New Drug Developments
For the past 10 years, standard therapy has been some form of pegylated interferon and ribavirin for 24–48 weeks, 
based on genotype. The limitations of these medications are well known. For genotype 1, the most common 
genotype in the United States and Europe, this has produced an SVR ( sustained viral response/equated with 
cure) rate of only about 40%. Pregnant patients or those with advanced renal disease are unable to use ribavirin. 
Likewise, interferon therapy excludes patients with autoimmune diseases, severe depression and mental illness, 
decompensated liver disease (Child-Turcotte-Pugh score more than 6), or decompensated cardiac or pulmonary 
disease. In addition to contraindications, side effects and low response rates have led to investigations for 
treatment alternatives. 
New drug therapies such as protease and polymerase inhibitors called new direct-acting antivirals (DAAs) have 
been developed over the last decade. In genotype 1 patients, very promising results have been reported when the 
protease inhibitors telaprevir or boceprevir (and other drugs in earlier phase studies) is added to the standard of 
care (SOC). The final results of  phase III studies have shown that SVR rates are increased from less than 50% 
(PEG-IFN plus RBV) to 70% (in PEG-IFN plus RBV plus the protease inhibitor).Overall, protease inhibitors hold 
promise in treating patients with chronic HCV, with improvements in responses to up to 80% in those undergoing 
first treatment, in those who have previously failed treatment and in those co-infected with HIV.Beginning in mid-
2011 in the USA, both telaprevir and boceprevir were approved for use in conjunction with pegylated interferon and 
ribavirin for the treatment of hepatitis C.  These drugs have now been approved for use in most European countries 
including Ireland.
While DAAs provide a tremendous improvement in SVR for many patients there are still treatment failures, side 
effects, and many patients excluded. Ongoing research supports their successful use as a first line treatment 
as well as in previous non-responders. The newer drugs provide an opportunity to treat these patients, most 
with mid to later-stage disease who cannot wait for additional options. Anaemia  may be a problem with the 
addition of these medications as well as new gastrointestinal side effects and rashes, which may be an important 
consideration in patient tolerance and selection of DAA.There is cross-resistance among the NS3/4A drugs, and 
therefore treatment failure/resistance to one drug in this category will likely be seen in all of them.
 New promise is anticipated with the polymerase inhibitors and other agents targeting cyclophilin or other 
intracellular proteins. Current DAA medications do show some efficacy against alternate genotypes and this 
expanded efficacy will likely be true for the newer generations which are currently in the pipeline.
The longer-term picture for the treatment of hepatitis C will likely include a cocktail of several different DAA 
medications targeting different sites. 
An important point in the treatment of HCV is that, as opposed to HIV or HBV, a cure is possible. Directly acting 
antivirals provide the opportunity to reduce treatment times in many patients and may increase cure rates to up 
to 70% or more. We are seeing new side effects and new resistance patterns as we employ DAA, but  literature 
is currently reporting improved tolerability of later generation drugs, new targets of action, innovative ways to 
approach resistance, efficacy with alternate genotypes, and the success of interferon free regimens. We anticipate 
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well tolerated cocktails of oral medications in the not too distant future, which will simplify the management of this 
infection.
Advances have also occurred in the diagnosis of complications of hepatitis C infection.  Hepatic ultrasonic 
transient elastography is a new, non-invasive, rapid method to evaluate liver fibrosis.  The patient does not require 
admission, and the procedure does not have to be performed in a hospital setting, unlike liver biopsy.  Fibrosis is 
estimated by the measurement of liver stiffness.  A reduction in elasticity can relate to fibrosis or cirrhosis. 
In Ireland some centres have applied this technology and it has proven popular with patients.  Some patients have 
used the information from the results of the scan to alter their alcohol and drug intake.  It has also highlighted the 
desirability for treatment in individual cases where this was previously unquantifiable. 
Previously, therapy was indicated for chronic hepatitis C infection if there was established moderate to severe 
activity or significant fibrosis documented on liver biopsy. This approach has been influenced by three issues. 
Initially, treatment outcomes for interferon monotherapy were poor with overall response rates in the region of 
24%.  Since the introduction of combination therapy, response rates have increased to over 50% in genotype 
1 patients and over 80% in genotype 2 & 3 patients. Therefore with improved outcomes, the risk benefit ratios 
of treatment have altered, significantly favouring the treatment of chronic hepatitis C infection. Secondly, cost 
modelling based on combination therapies has demonstrated that treatment is beneficial even in patients with 
minimal histological damage. Thirdly, the evolution of technologies to evaluate the stage of histological injury (as 
discussed above), avoiding the need for liver biopsy, should enable more timely access to treatment. Ultimately, 
more patients with chronic hepatitis C infection can now be offered individualised treatment.
This is a technical overview of new and emerging therapies. How these therapies will be made available to patients 
and the more detailed clinical assessments and associated factors in relation to translating new drug discovery into 
clinical action are the subject of guidelines being developed by clinical experts.
7.2.2 Treatment in general practice
Considerable work has been done by the Dublin Area Hepatitis C Initiative Group (DAHCIG) in recent years.[6]  The 
initiative included the development of clinical guidelines derived from scientific evidence and expert consensus 
obtained using the Delphi technique.1  The guidelines cover general care, immunisation, screening, diagnosis, 
work-up and onward referral to specialist services.  A complex pilot intervention study using these guidelines 
was designed and evaluated.  The evaluation to date has concluded that general practice has an important 
role to play in the care of people at risk of hepatitis C.  With appropriate support, GPs can effectively implement 
current best practice among groups who are infected.  The need for additional supports is emphasised by the 
DAHCIG, particularly the development of a primary care nurse liaison service.  A more detailed description of these 
guidelines can be found in Appendix 11.
7.3 Current situation
Different patient groups with hepatitis C, who could potentially benefit from treatment, have been identified. 
1. Injecting drug users (current and former) of whom approximately 10,000 are infected with hepatitis C.  This 
number is an estimate based on the number of drug users in treatment .
2. Patients infected through contaminated blood and blood products (often referred to collectively as ‘State 
infected’).  These patients, of whom there are approximately 1,700, link well with services and can avail of 
specialist services in eight designated hospitals.
3. Patients who are referred to as sporadic cases of infection as no obvious source of infection can be determined.  
These patients are usually diagnosed through their attendance at specialist services.  Improved national 
surveillance should prospectively provide data on the numbers of patients affected.
4. Immigrant populations including asylum seekers.    Asylum seekers are currently the only migrant population 
who are offered screening.  Incomplete enhanced surveillance data precludes an estimation of the numbers 
affected.
5. Patients co-infected with hepatitis C and HIV.  These patients are usually cared for by the infectious disease 
services at three sites nationally
6. Patients infected with hepatitis C who also drink alcohol are at particular risk, particularly if drinking levels are 
at or above the Irish norms.  It is important that any treatment programme for any people who are infected 
with hepatitis C would address the alcohol issue and make arrangements for alcohol reduction strategies to be 
made available to the individual patients.
1  The Delphi technique involves an iterative approach, designed to measure consensus among individual responses. Face-to-face participation is 
not required. A series of questionnaires interspersed with information summaries and feedback from preceding responses are usually employed.
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Hepatitis C treatment in Ireland is in line with international guidelines.  Treatment is most commonly delivered in a 
hospital setting, in centres with a special interest in hepatitis C. 
MATER HOSPITAL/THOMPSON COMMUNITy DRUG TREATMENT CENTRE COLLABORATION
The Mater Hospital / Thompson Community Drug Treatment Centre collaboration for the treatment of patients with hepatitis C was 
established in 2006.  The collaboration was initiated because many patients in the community with hepatitis C who were referred to 
the hospital for evaluation were not completing the evaluation process.  Several reasons for patients not being fully evaluated related 
to difficulties communicating with them in the community e.g. appointments were not being made appropriately, patients were 
moving homes frequently and appointments were going to the wrong address.
Currently the staff of the infectious disease (ID) clinic in the Mater hospital (nurse specialist, secretary, ID consultant) meets monthly 
with the staff of the Thompson centre (nurse, administrator, GP coordinator) to review patients who are eligible for treatment, stable, 
and motivated to complete treatment.  An initial evaluation takes place at the Mater hospital ID clinic to familiarise patients with the 
hospital and to link them with the infectious diseases clinic and Mater hospital consultations, if it is deemed necessary in the future.  
The evaluation includes baseline bloods, diagnostic tests, consents and scheduling of further investigations.  The Mater hepatitis C 
nurse specialist plays a key role in co-ordinating services.  Subsequently all visits, before and after the initiation of hepatitis C specific 
therapy, take place at the Thompson Centre where the Mater nurse specialist attends once a week.  Problems are discussed weekly 
with the Mater nurse specialist, GP coordinator and ID consultant as needed.  Monthly meetings of the joint Mater/Thompson Centre 
team are used as a forum for case management of those already on treatment as well as evaluation of those who are eligible for 
treatment.  
Through the application of this model of community/hospital partnership, more patients with hepatitis C and ‘stable’ substance 
misuse are receiving HCV treatment with good adherence and follow-up.
Vignette 2: An on-site programme at the Thompson Centre in association with the Infectious Disease services 
at the Mater Hospital, Dublin 
Several models of care can currently be described in Ireland.  Different sectors of the healthcare services are 
involved with different links between the services.  The services principally involved in the treatment and 
management of patients with hepatitis C are: 
•		Hospital	based	consultant-led	services	 	 	 	 	 	 	 	
These services are provided by the specialities of hepatology, gastro-intestinal medicine and infectious 
diseases.  Patients are managed on a day to day basis by nurse specialists with consultant supervision. 
•		Drug	treatment	services		 	 	 	 	 	 	 	 	 	
Four sites in the Dublin area deliver anti-viral treatment to patients at the clinics where they receive 
methadone treatment.  
•		Prison	services	 	 	 	 	 	 	 	 	 	 	
  An infectious disease consultant has been appointed to Wheatfield and Cloverhill prisons, resulting in 
improved screening and referral rates for hepatitis C. Expansion of these services is recommended.
•		Services	provided	by	GPs	specialising	in	substance	abuse
•		Community	general	practice	services		 	 	 	 	 	 	 	
The methadone protocol has been in existence since 1998.  Approximately 3000 patients attend GPs in 
community for methadone treatment.  Many of these patients are hepatitis C positive.
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 HEPATITIS C TREATMENT PROGRAMME AT THE DRUG TREATMENT CENTRE BOARD 
In 2003, a pilot on-site hepatitis C programme was established at the Drug Treatment Centre Board (DTCB) incorporating directly 
observed hepatitis C treatment.  Directly observed therapy (DOT) has been shown to work well for the treatment of HIV and TB in 
drug users on methadone maintenance.  The rationale for the pilot programme was to treat both a patient’s hepatitis C infection and 
drug addiction at the same site with a view to improving the adherence of patients to a hepatitis C treatment schedule.  The aim was 
to demonstrate a ‘proof of concept’; that patient retention in treatment can be improved if therapy is directly observed and delivered 
in a specialist drug treatment setting with appropriate on-site medical and psychiatric support.  The medical care was delivered under 
the guidance of a Consultant in Infectious Diseases based at St. James’s Hospital (SJH).  Patients received regular psychiatric review 
and were monitored for psychiatric complications of therapy and potential relapse into active addiction. Day to day monitoring was 
coordinated by an appointed nurse at the DTCB. 
Vignette 3: An on-site programme at the Drug Treatment Centre Board in association with the Infectious 
Diseases services at St. James’ Hospital, Dublin 
Care of infected drug users can be limited by 
- chaotic lifestyles
- social deprivation and exclusion
- imprisonment
- poor attendance at clinic appointments
- failure to adhere to treatment 
- unsuitability for treatment as a consequence of ongoing drug or alcohol use.
Care may also be hindered by suboptimal social, childcare and addiction support. 
Most services are supported by hepatitis C liaison clinical nurse specialists (HCLNS) who can be based in 
hospitals or in the community.  Liaison nurse specialists play a role in enabling a patient to enter treatment and in 
maintaining patients in treatment programmes. A HCLNS in the former Northern Area Health Board was appointed 
in 2002 and facilitates the delivery of hepatitis C treatment to drug users in various drug treatment clinics in the 
north side of Dublin and to drug users attending GPs in this area. Clinical nurse specialists based in the community 
(e.g. in the addiction services) liaise with specialist services to enable patient-centred care. Clinical nurse specialists 
in hospital-based positions work collaboratively with relevant primary healthcare providers as appropriate. Medico-
legal concerns exist with regard to clinical responsibility.  These concerns may be addressed by ensuring that 
all nurses work under the clinical guidance of the gastroenterologist or infectious disease consultant in matters 
relating to hepatitis C management and in collaboration with primary healthcare workers for primary care related 
matters.  
HEPATITIS C TREATMENT AT ST JAMES’ HOSPITAL IN CONJUNCTION WITH THE  
DUBLIN SOUTH-WEST ADDICTION SERVICES
The Hepatology team at St James’ Hospital offers a comprehensive range of services and sees approximately 4,000 hepatitis C 
patients per year. Clinics have been developed to meet the needs of the various client groups who access these services, including 
injecting drug users (IDUs) infected with hepatitis C. 
Since late 2005, a clinical nurse specialist provides a nurse-led hepatitis C education and treatment clinic for IDUs who attend a 
Consultant Hepatologist.  This nurse-led clinic is provided in collaboration with the GP co-ordinator for the local drugs service at 
community based methadone services and at SJH outpatient departments. 
An audit performed at eighteen months demonstrated that patients can be successfully treated at the addiction centres with 
sustained virological responses comparable to hospital based services once treatment has commenced. However, following initial 
assessment, there was a significantly longer lead-in time before treatment was commenced. Patients were also significantly more 
likely to refuse, default or become unsuitable for treatment compared with hospital-based patients. While on treatment, these 
patients required more interventions than hospital-based patients. However, rates of recidivism for drug use were not increased. 
Therefore while this service is invaluable in treating a difficult population, consideration must be given to the efficacy and efficiency of 
treating this population in directing further service provision.
 
    
Vignette 4: An on-site programme at the Castle Street HSE Addiction Clinic, Dublin 8 in association with the 
hepatology services at St. James’s Hospital, Dublin 
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7.4 Appraisal of the current situation 
Comprehensive services have been put in place for patients who acquired hepatitis C through contaminated blood 
and blood products.  However, the needs of those who have acquired hepatitis C through other means have not 
been adequately addressed to date.  The establishment of a national register will provide accurate data on the 
number of people who are infected, the number who are in treatment and the number awaiting treatment, as 
per recommendation 4, chapter 4.  The population prevalence study (recommendation 6) and modelling exercise 
(recommendation 7) recommended in Chapter 4 will also provide invaluable data to enable effective service 
planning.  
Limitations to the care of IDUs who are infected have been described above.  Models of care that have been 
designed to try and address some of these issues have also been described.   However it is estimated that the 
number who are in treatment or who have been treated is outweighed by the number of people who could benefit 
from but have been unable to access treatment for a variety of reasons.
Other subgroups of the population also face difficulties in accessing services.    Due to the nature of 
accommodation provided to asylum seekers through the dispersal system many asylum seekers are at risk of loss 
to medical follow up in the community.  Concern has been raised that the government’s current integration strategy 
excludes asylum seekers. [55] [56]  Other immigrants may also have difficulty accessing services, both for hepatitis 
C infection and addiction, due to a lack of familiarity with the Irish health care system and language barriers.
The reliance on the availability of escorts for prisoners to attend out-patient appointments can reduce compliance.  
Lack of needle exchange in prison reduces illicit drug stability and therefore suitability for treatment.  
Many centres that are currently providing hepatitis C treatment are doing so with externally sourced (i.e. non-
Exchequer) funding. This funding is not recurrent leading to fluctuating numbers of patients in treatment and 
termination of treatment for some prior to completion of the recommended course.
With regard to community hepatitis CNS posts, two additional community posts were approved in Dublin for the 
South West Addiction Service and the East Coast Addiction Service. The post in the south west has been filled.  No 
equivalent position exists outside Dublin.  
Many patients choose to defer or refuse treatment for various reasons which may be personal, financial or social.  
Until such time as a patient chooses to engage in therapy for hepatitis C, that patient should continue to be 
assessed in the specialist centre.
7.4.1 Issues identified by the hepatitis C community liaison nurse specialist service
•		The	widespread	prevalence	of	hepatitis	C	amongst	drug	users	means	that	the	liaison	service	is	completely	
over-stretched resulting in inadequate service delivery. 
•		Many	service-users	require	long-term	follow-up	due	to	the	chronic	nature	of	hepatitis	C	and	a	predominance	
of genotype 1 infection.  This significantly impacts on the capacity of secondary services.  Waiting times for 
appointments, liver biopsies, psychiatric screening and engagement in treatment at hospital level have 
lengthened. 
•		The	impact	of	chronic	hepatitis	C	on	the	drug	users	can	present	a	range	of	complex	health	needs.	Many	of	
these needs cannot be met at secondary level and require collaboration with primary services to facilitate 
effective interventions.
•		Effective	monitoring	and	follow-up	of	patients	on	treatment	relies	on	staff	resources,	with	an	emphasis	on	
nurse specialists as co-ordinators of care. 
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COMMUNITy HEPATITIS C LIAISON NURSE SPECIALIST
In December 2002, the Addiction Services of the former Northern Area Health Board employed a Hepatitis C Liaison Nurse Specialist 
(HCLNS) to assist in the clinical management of hepatitis C in ‘Dublin North’, ‘Dublin North East’ and ‘Dublin North Central’. The role 
encompasses five core functions:
· clinical caseload, 
· patient advocacy, 
· education & training, 
· audit & research,
· resource person. 
The position was approved at clinical nurse specialist level in 2005 by the National Council for the Professional Development of 
Nurses & Midwives.  
Key to the HCLNS role is the shared-care programme between hospital-based specialist services for hepatitis C and community-based 
addiction services.  A collaborative link between the two services optimises the care patients receive.  This link is achieved by the work 
of the HCLNS in co-ordinating clinical support at community level and includes:
· assistance with a holistic assessment of clinical status, client’s understanding of diagnosis & stability and referral of patients to 
hospital follow-up and to support services 
· psychosocial support
· preparation of patients for diagnostic procedures 
· facilitation of hepatitis C treatment processes in the community.
Treatment in the community occurs under the clinical direction of hospital-based hepatology or infectious disease consultants.
This model of care is consistent with the strategic direction of the HSE: providing services in a primary care setting, whilst easing the 
burden on secondary services and delivering timely and patient-focused care (DOHC, 2001).
Vignette 5: The role of the community hepatitis C liaison nurse specialist
7.4.2 Issues identified for community-based GPs
•		An	increasing	amount	of	addiction	related	care	is	being	delivered	in	general	practice.		The	observed	
prevalence of known hepatitis C infection of 73% in a study carried out in the former ERHA [5] indicates the 
relevance of this issue for GPs.
•		Inconsistencies	in	the	management	of	patients	in	general	practice	have	been	reported.	[6]
•		Access	to	community	diagnostic	services	is	poor	particularly	for	clinics	that	operate	out-of-hours.		Many	
methadone clinics operate out-of-hours providing replacement therapy to stable patients before or after 
work.
•		Qualitative	research,	carried	out	on	a	small	purposive	sample	of	GPs	providing	methadone	maintenance	in	
the former ERHA, reported the principal barriers to guidelines being implemented in their practice as
o Lack of resources at practice level
o Attitudes of GPs and patients towards hepatitis C
o Lack of time on the part of GPs 
- 43 -
National Hepatitis C Strategy 2011-2014 HSE
o 
o 
o 
o 
o 
•		Implementation	of	guidelines	on	the	management	of	drug	users	attending	general	practice	requires	
increased awareness, education, and both organisational and clinical supports for GPs.  
A GENERAL PRACTICE INITIATIVE (HSE EASTERN REGION) TO IMPROVE HEPATITIS C CARE OF 
CURRENT OR FORMER INJECTING DRUG USERS
In Ireland and the EU, addiction related care is increasingly delivered in primary care. Research conducted in 1999 in Ireland 
demonstrated that hepatitis C infection was common among patients attending general practice for methadone treatment, and 
highlighted a need for additional interventions to enhance screening. 
Clinical guidelines were developed for the management of hepatitis C among drug users in general practice and an intervention to 
implement these guidelines was designed and evaluated. 
The clinical guidelines included advice on the primary and secondary prevention of harm associated with hepatitis C infection. 
Clinical and organisational supports were incorporated into the intervention model and consisted of CME-accredited practice based 
education and a nurse to liaise with external agencies, assist clinical patient care, initiate / coordinate liver specialist referrals and 
support patients being assessed for treatment.
This initiative was evaluated by a randomised trial in 25 GP practices.  At baseline, 77% had been screened for hepatitis C; of those 
who were HCV positive, 30% had been referred for assessment by a liver specialist. 
After six months, patients attending practices where the intervention was in place were found to be significantly more likely to have 
been screened for hepatitis C, less likely to have provided a urine sample that contained an illicit drug metabolite and more likely to 
have been given advice on reducing alcohol consumption. Hepatitis C positive patients were also more likely to have been referred to 
a liver specialist. 
The findings of this evaluation highlight the importance of evidence-based approaches in addressing hepatitis C-associated harm and 
the central role of general practice, with appropriate resources and professional frameworks, in any strategic response.
Vignette 6: A general practice initiative (HSE Eastern Region) to improve hepatitis C care of current or former 
injecting drug users
7.4.3 Issues identified by GP specialists in substance abuse (GPSSA)
•		Hepatitis	C	is	an	addiction	issue	as	many	are	infected	through	injecting	drug	use.		This	is	also	relevant	to	the	long	
term management of the infection by the patient, particularly with regard to re-infection and alcohol use.
•		Multiple	issues	(personal,	social,	family,	medical,	legal,	drug-related,	alcohol	related,	psychological	and	
psychiatric) which affect a person’s drug-use also affect their ability and suitability to undergo pharmacological 
treatment. Therefore not all patients who are hepatitis C RNA positive will be suitable for anti-viral treatment.
•		Communication	between	treating	doctors	and	between	doctor	and	patient	are	essential,	particularly	during	
pharmacological treatment.
•		GPSSAs	who	are	involved	in	the	management	of	patients’	addiction	and	infection	should	be	given	the	resources	
to develop their interest and skills in delivering care to their patients in collaboration with other groups within and 
outside the addiction services.
•		Clinics	in	the	addiction	services	need	to	be	adequately	resourced	to	help	chaotic	patients,	including	those	who	are	
not immediate candidates for pharmacological treatment. 
- 44 -
National Hepatitis C Strategy 2011-2014 HSE
THE EAST COAST AREA INTEGRATED SHARED-CARE PROGRAMME FOR THE MEDICAL 
MANAGEMENT OF HEPATITIS C IN THE ADDICTION SERVICE
This programme offers appropriate medical management of hepatitis C by integrating a patient’s addiction treatment with their long 
term management of hepatitis C. The programme is multidisciplinary (GPSSA, psychiatrist, nurses, pharmacist, counsellors and other 
staff), consensual and patient driven.
Patients who are PCR positive are referred (not triaged) to the hepatology services in St Vincent’s Hospital and a follow-up system 
exists for those who miss appointments.  The hepatology services – including the Consultant Hepatologist and the hospital-based 
nurses - work in close co-operation with the clinical staff in the addiction centre to deliver integrated hepatitis C and addiction 
treatment for the individual patient. An unparalleled familiarity with the patient’s personal, social, family, medical and drug history 
and regular daily contact with the patient provides for
•	an	appropriate	level	of	care	to	all	patients,	chaotic	and	stable
•	a	comprehensive	level	of	support	before,	during	and	after	treatment
•	a	heightened	ability	to	detect	adverse	treatment	effects	including	treatment-induced	depression	and	suicidal	ideation	
•	a	reduced	likelihood	of	return	to	drug	and	alcohol	abuse	while	on	treatment
Patients, who do not attend for treatment, those who do not have a sustained virological response (SVR) after treatment or those who 
become re-infected, are the largest patient group for the addiction services and receive ongoing follow up.  Annual PCRs are carried 
out on patients who continue to potentially expose themselves to infection.
The integrated addiction/infection management approach lends itself to post treatment surveillance, including regular evaluation of 
post treatment drug use (including alcohol) and its effect on long term treatment outcome, and forms the basis of an ongoing plan 
for patients when they move on to community based GPs.
This near-patient, integrated model of care uses the resource of a team who knows their patient, their circumstances and their drug 
use, to effectively deliver both addiction and hepatitis C related treatment and support.  
Screening has been successfully piloted in the Addiction Service in the East Coast Area. This has reached patients who did not 
previously attend Hepatology when referred and indicates that advanced liver disease is common in patients attending the Addiction 
Service.
Vignette 7: An on-site programme at the Patrick Street HSE Addiction clinic in Dun Laoghaire, Co. Dublin, in 
association with the Hepatology services at St. Vincent’s Hospital, Dublin 
7.5 Recommendations
The principle that treatment should be available in an equitable manner for all those infected with hepatitis C, 
irrespective of mode of acquisition, has been firmly agreed by the treatment subgroup and endorsed by the main 
working group.
A set of recommendations has been drawn up by the treatment subgroup which outlines what the HSE and other 
agencies should provide and facilitate in order that accessible, equitable, quality care can be delivered to all 
patients infected with hepatitis C in Ireland as a matter of priority.
Improving access to treatment and supporting patients through treatment will reduce the progression from viral 
infection to liver damage for many patients.  It should also contribute to a reduction in the prevalence of hepatitis C 
infection, thus reducing the associated clinical and social burden of the disease.
Expert Guidance on Clinical Issues
Challenges can arise in the diagnosis of hepatitis C and the subsequent management of patients e.g. the ongoing 
long-term monitoring and management of 
- patients who are antibody positive but in whom hepatitis C RNA is not detected 
- patients who choose not to avail themselves of, or are not ready or suitable for treatment.  
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For these patients, clinical pathways should be developed to assist them in working towards treatment suitability.  
Standardised guidelines reflecting best practice should be readily available to all health care providers, particularly 
community GPs.
Recommendation 29 •		Establish an expert group to provide guidance on clinical issues. 
•		Develop standard protocols for testing, diagnosis, evaluation, referral for treatment, 
monitoring of treatment and monitoring of patients not on treatment.  
•		Monitor and evaluate the implementation of these guidelines.
Organisation Responsible Expert Group
HIQA (Health Information and Quality Authority)
Recommendation 30 Establish a postgraduate diploma in hepatitis C management for physicians and nursing staff
Organisation Responsible Accredited third level academic institution 
Tendering process should be overseen by the expert group
Barriers to treatment uptake and adherence
Barriers to treatment uptake and adherence to treatment, once initiated, should be addressed, be they social, 
psychological or related to drug or alcohol use.  Peer support is recognised as an effective means of promoting 
treatment and compliance and peer educators should be appropriately trained as in recommendation 11, chapter 5. 
Recommendation 31 Provide patients, particularly those with chaotic lifestyles and other social problems, with 
practical supports to enable them to attend for and adhere to treatment e.g. child-care
Organisation Responsible Primary Care Teams
Recommendation 32 Address alcohol issues and provide alcohol reduction strategies for those patients infected 
with hepatitis C who require them
Organisation Responsible HSE – Drugs and Alcohol services
Hepatitis C care in custody
As previously stated the prevalence of hepatitis C amongst prisoners with a history of injecting drug use is 
particularly high.   Those serving custodial sentences should be offered hepatitis C care in line with best practice 
models 
Recommendation 33 Develop, implement and evaluate a treatment model appropriate to the prison setting on a 
national basis
Organisation Responsible Expert Group in conjunction with the IPS
Meeting the needs of all patients infected with hepatitis C
As outlined in section 7.4, the needs of patients infected with hepatitis C through means other than contaminated 
blood products have not been formally assessed.  As part of a needs assessment, international literature should 
be critically reviewed to evaluate different models of care that exist in terms of efficiency and effectiveness.  An 
economic appraisal of effective models should also be carried out.   The merits of increasing the availability of 
portable ultrasonic diagnostic equipment should be explored in terms of diagnostic accuracy and potential cost-
savings.
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Recommendation 34 Undertake a formal assessment of the needs of individuals infected with hepatitis C, other 
than through contaminated blood and blood products
Organisation Responsible HSE 
Clinical Nurse Specialist staffing requirements for hepatitis C treatment
The number of CNSs working in the area of hepatitis C should be expanded to meet the demand for patient 
treatment.  A standardised approach should be adopted to the establishment of nurse specialist posts nationally, 
both in the addiction services, prison services and hospital-based services.  The needs assessment recommended 
above will establish potential service demands around the country and the number of CNS posts required. 
Recommendation 35 Further develop the number of hepatitis C CNS posts based on the findings of the needs 
assessment in recommendation 34 
Organisation Responsible HSE
Delivery of hepatitis C care to patients through primary care services
The delivery of services within the primary care setting should be maximised to alleviate the burden of work on 
hospital services and to provide care to patients in a setting that is most convenient to them.  Weekly GP visits by 
stable patients for methadone substitution could be linked to hepatitis C treatment and monitoring.  This work 
would be supported and facilitated by community HCLNS and by increased access to community diagnostics (see 
recommendation 23).
Recommendation 36 Develop the role of suitably trained general practitioners in facilitating treatment monitoring 
in the community 
Organisation Responsible HSE and ICGP (Irish College of General Practitioners)
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8. Conclusion
The State has put in place, underpinned by legislation, a comprehensive response to hepatitis C for those who 
became infected through “state infection”. 
The recommendations of this report are framed so that all persons infected with hepatitis C will have access to a 
range of medical treatments and other control measures.
There are many challenges in achieving this, and what is set out here is an action plan over 4 years.  We are 
conscious that all cannot be done at once and we have prioritised some actions.  We are also conscious of the 
need to get the right balance between a standardised approach while allowing flexibility within regions and by 
clinical services.  There are a number of models of treatment described in Chapter 7.  Recommendations are made 
with regard to the need for a formal needs assessment and economic evaluation of existing responses.  There are 
many gaps in data and epidemiology which need to be filled.  We have emphasised education, prevention and 
communication with people who are infected or at risk of infection.
There are a number of further and deeper levels of information and understanding that are required and for 
that reason we recommend the establishment of an expert working group to take forward some of the specific 
treatment based recommendations.  
We believe that now is an opportune time to develop a cohesive and co-ordinated strategy for the care of all 
patients infected with hepatitis C in Ireland. With the recent introduction of a unified national structure for our 
health services the opportunity to develop a nationwide approach to this disease should not be missed.  Patient-
centred care is one of the core values espoused by the current health services administration.  This paradigm of 
care aligns itself very much with the philosophy behind our document.  We believe if our recommendations are 
implemented in good faith that the response to hepatitis C infection will improve considerably at a population level 
over the next 3 years.
 
9. Action Plan
This chapter lays out an action plan to improve the care of hepatitis C infected patients in Ireland.   The plan is 
laid out in tabular format and pulls together the recommendations that have been made in the different chapters.  
Many recommendations are budget neutral and could be implemented without delay.  Some simple steps could be 
taken without any new investment and would lead to a considerable increase in the efficiency of current systems 
and the care delivered to patients.
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APPENDIX 5: HEPATITIS C ASSOCIATED HEALTHCARE UTILISATION
The Hospital In-Patient Enquiry (HIPE) System and the Primary Care Reimbursement Service (PCRS) provide 
limited information on the use of HSE healthcare services for individuals with hepatitis C.
Hepatitis C Associated Hospital Utilisation.
As outlined in Chapter 2, section 2.2.1, the HIPE System contains a record for each discharge following an episode 
of care from an acute hospital in Ireland.  The condition that caused the patient to seek care is recorded as are 
other co-morbid conditions.  Hepatitis C infection is a chronic condition which may be recorded as a co-morbid 
diagnosis for patients receiving care for other conditions or may be the cause of admission.  It is important to 
re-emphasise that the HIPE system is based on individual discharges and not individual patients.  For these 
reasons, hospital utilisation data associated with Hepatitis C infection require careful interpretation.
Table A presents data for hepatitis C associated hospital utilisation in 2005 and 2006 from the HIPE system.  In 
extracting this data, the International Classification of Diseases (ICD) was used to define groups of conditions 
related to hepatitis C infection, drug use and complications of liver disease.  The total number of discharges, bed 
days and ICU bed days associated with the conditions are shown.  An approximate cost, estimated by matching the 
Diagnostic Related Group (DRG) associated with each episode of care to a “ready reckoner” cost provided by the 
Casemix Unit of the HSE, is also displayed.  
A number of observations are made concerning these data:
•		There	is	an	increase	in	the	number	of	discharges	between	2005	and	2006,	approximately	13%	to	90%	depending	
on the conditions.  This may reflect changing patterns in Hepatitis C associated hospital utilisation.  However, 
it may also reflect increased identification of infection and changing patterns in coding of discharges following 
episodes of care.
•		A	large	number	of	episodes	of	care	associated	with	hepatitis	C	are	recorded	with	a	diagnosis	of	acute	infection	
(ICD 10 B171), approximately 43% in both years presented.  This is surprising as the majority of cases of acute 
Hepatitis C infection are sub-clinical in nature and may reflect an opportunity to improve the quality of coding of 
discharges following episodes of care.
•		Approximately	18%	and	24%	of	discharges	with	any	diagnostic	code	for	hepatitis	C	infection,	following	episodes	
of care in 2005 and 2006, also had a code indicating a diagnosis of drug use.  This is unlikely to reflect the 
epidemiology of infection in the community.  It is more likely to reflect patterns of coding of co-morbid drug use or 
varying patterns of hospital utilisation between patients with and without co-morbid drug use.
•		Approximately	6%	of	discharges	following	an	episode	of	care	with	any	diagnosis	of	hepatitis	C	and drug 
use, recorded in 2005 or 2006, also had a diagnosis indicating a potential complication of this infection.  
Approximately 9% and 11% of discharges following an episode of care with any diagnosis of hepatitis C, recorded 
in 2005 and 2006 respectively, also had a diagnosis indicating a potential complication.  
•		In	2006,	discharges	following	an	episode	of	care	associated	with	HCV	and	a	complication	accounted	for	19%	of	
bed days, 32% of ICU bed days and 24% of the costs of discharges following an episode of care associated with 
hepatitis C.  This reflects the more intense utilisation of services by patients with complications.
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Hepatitis C associated drug utilisation
The Primary Care Reimbursement Service (PCRS) administrates a number of payment schemes for drugs and 
services including the “Hi-Tech Drugs” (HTD) scheme.  The HTD scheme provides arrangements for the supply and 
dispensing of High Tech medicines through community pharmacies which are generally prescribed or initiated in 
hospital.  Drugs reimbursed under the HTD scheme include a number of drugs used in the treatment of Hepatitis 
C infection: ribavirin, peginterferon alfa-2a, peginterferon alfa-2b, interferon alfa-2a and interferon alfa-2b.  While 
ribavirin is solely indicated for the treatment of chronic hepatitis C infection, interferon-based drugs have wider 
indications.
The PCRS Statistical Analysis of Claims and Payments provides the most recent data on the number of 
prescriptions and ingredient costs for drugs reimbursed under the HTD scheme.  However, this information is not 
provided on a per-patient basis and it is not linked with a diagnosis.  This limits the interpretation of the data in 
table B as not all prescriptions were for the treatment of hepatitis C.  In addition, combinations of drugs are not 
presented.  
Table B:  Prescribing frequency and ingredient cost of drugs indicated for the treatment of Hepatitis C 
infection, reimbursed under the HTD scheme in 2006.
Drug Prescribing 
frequency
% of HTD scheme 
total
Ingredient cost (€) % of HTD scheme 
total
Ribavirin 1125 0.45 773110 0.46
peginterferon 
alfa-2a
1170 0.47 1221630 0.73
peginterferon 
alfa-2b
522 0.21 254920 0.15
interferon alfa-2a 463 0.19 158493 0.09
interferon alfa-2b 818 0.33 565878 0.34
Source: Primary Care Reimbursement Service, Statistical Analysis of Claims and Payments 2006.
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APPENDIX 7 – CURRENT RECOMMENDED DATA ITEMS FOR LABORATORy 
NOTIFICATIONS OF INFECTIOUS DISEASE
Data Item Description
Surname Surname of patient
First Name Firstname of patient
Address 1
Address 2
Address 3
County County where patient resident
Contact Tel No. Patient's contact telephone number
Gender M, F, NK
DOB Date of Birth
Age Age of patient
Patient Type In-patient, Out-patient, GP patient
Hospital Number Patient Hospital number
SpecimenLabID Specimen number
Specimen Type Type of specimen e.g. blood, csf, stool, urine etc.
Specimen Date Date Specimen taken
DateTest Result Date Laboratory diagnosis was made
Or
ga
ni
sm
 
De
ta
ils
Organism Description
Genus, Species, Type (or equivalent) 
Also Other Details if available (e.g. phage type, subtypes, 
markers for HepB etc)
Ph
ys
ic
ia
n 
De
ta
ils Referring Clinican/GP 
Details Name and address of referring clinician or GP
Additional Comments Insert clinical comments and/or epidemiological information if relevant
Outbreak Code Code assigned to outbreak
Note: Laboratory Name, Name and Address of Notifier and Date Notification by Laboratory 
should also be provided by lab when notifying Medical Officer
Address where patient resident
Infectious Disease Notifications
Suggested Data Items for Labs to report to Public Health
Pa
tie
nt
 D
et
ai
ls
Sp
ec
im
en
 D
et
ai
ls
Ad
di
tio
na
l 
De
ta
ils
Laboratory Reporting Template.xls 16/03/2004
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APPENDIX 8 - GUIDELINES FOR THE MANAGEMENT OF NOTIFICATION OF 
HEPATITIS C TO DEPARTMENTS OF PUBLIC HEALTH 
 
 
Guidelines for the Management of Notification of Hepatitis C to Departments of Public Health        –       December 2007 
 
 
 
 
Clinical description 
In symptomatic cases, clinical picture compatible with hepatitis, i.e., discrete onset of symptoms 
and/or jaundice or elevated serum aminotransferase levels. 
Asymptomatic cases are common. 
 
Laboratory criteria for diagnosis 
One of the following: 
 Detection of hepatitis C virus (HCV) specific antibodies 
 Detection of HCV nucleic acid from clinical samples. 
 
Case classification 
Possible: N/A 
Probable: N/A 
Confirmed: A case that is laboratory confirmed 
 
Note 
This case definition includes all laboratory confirmed cases; the EU definition is restricted to 
symptomatic cases only. 
GUIDELINES 
for the Management of Notification of Hepatitis C 
to Departments of Public Health. 
 
The notification of hepatitis C cases is an important step in the prevention and control of hepatitis C 
in Ireland.  It is essential that all cases are notified in a timely manner to ensure effective 
surveillance, prevention, early identification of incidents and prompt control and management of 
outbreaks. 
 
 The Infectious Diseases Regulations 1981 amended by ID (Amendment) (No 3) Regulations 
2003  (SI No 707 of 203) requires that medical practitioners, including clinical directors of 
diagnostic laboratories must notify the Medical Officer of Health in the Department of Public 
Health of certain infectious diseases. 
 Hepatitis C became notifiable under this legislation on January 1st 2004. 
 Hepatitis C is notified on the standard Notification of Disease form (Appendix 1) 
 The template for notification of hepatitis C from laboratory → Medical Officer of Health → 
HPSC are attached (Appendix 2 & 3).  This process usually takes place through CIDR for most 
parts of the country. 
 
 The Case Definition for Hepatitis C (Hepatitis C Virus) from NDSC Case Definitions Version 
1.1 is available at www.hpsc.ie. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hepatitis C 
(Hepatitis C virus) (EU) 
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Guidelines for the Management of Notification of Hepatitis C to Departments of Public Health        –       December 2007 
 
The Public Health investigation of hepatitis C cases should be carried out for the following reasons: 
 The prevention of secondary spread by advising on risk reduction measures and the 
protection of contacts. 
 To carry out enhanced surveillance of cases to provide epidemiological information to 
inform public health measures in particular to identify the likely source of infection and 
inform health service planning. 
 
 
ON RECEIPT OF A NOTIFICATION OF HEPATITIS C FROM A CLINICIAN OR A 
LABORATORY 
The Medical Officer of Health will:- 
 On receipt of notification check with local infectious diseases notification database or CIDR  
that case has not already been notified e.g. duplicate entries for persons who have regular tests 
to check viral status.  If previously notified by another source the new report is not set up as a 
new notification. 
 If not previously notified confirm the status of the case with the notifier (if known): newly 
diagnosed case or previously diagnosed case. 
 Enhanced surveillance information should be provided on all new notifications – either using 
the enhanced surveillance form (attached) or through CIDR system. 
 
If newly diagnosed case: 
1. If the case is newly diagnosed the MOH may or may not need to take further action depending 
on the information provided. 
(For example, if the case is identified as an injecting drug user (IDU) attending an addiction 
service that follows a defined protocol for providing advice minimising the risk of transmission, 
hepatitis A or B vaccination as appropriate, and investigation and referral as required, then no 
further public health action will be required). 
2. If the source of infection is not stated or is unknown, the MOH should discuss the case with the 
relevant clinician. 
 To obtain information on the case e.g. 
demographic, clinical, risk exposure category, likely source of infection as per enhanced  
surveillance dataset. 
 To determine and agree what further investigation is required e.g. to out rule a 
healthcare acquired infection. 
- 64 -
National Hepatitis C Strategy 2011-2014 HSE
 
 
Guidelines for the Management of Notification of Hepatitis C to Departments of Public Health        –       December 2007 
 To provide advice to the clinician in relation to appropriate clinical referral and 
      assessment. 
 To provide advice to the clinician in relation to the need for hepatitis A,     
      hepatitis B vaccination as appropriate for the case. 
 To ensure cases are advised on how to minimize risk of transmitting infection. 
3. Update notification as extra information becomes available e.g. genotype. 
 
 
If previously diagnosed case: 
Determine with the clinician  
 That case is receiving appropriate management with respect to 
- Advice on hepatitis A and hepatitis B vaccinations 
- Advice on minimising risk of transmitting infection 
 In most cases, no further public health action will be required. 
 Maintain a record of the notification and actions taken.   
 
 
 
Note – Except in exceptional circumstance contact with the case should only be 
made following discussion with the notifier and/or clinician  (either hospital 
consultant or general practitioner). 
APPENDIX 9 – RECOMMENDED ENHANCED SURVEILLANCE FORM FOR HEPATITIS C 
INFECTION
Enhanced Surveillance Form for
Hepatitis C
Patient Details
Comments
Thank you for completing this form
Forename initial
Age (years)
Sex Male Female Unknown
HSE Region County CCA/LHO
Country of birth If not Ireland, duration of residence in Ireland (years)
CIDR event ID Local IDSurname initial
Date of birth
Please complete this form for the first notification of a case of hepatitis C
Occupation
If none of the above
*The NVRL currently use the following antibody tests: MONOLISA, Centaur, Architect & Ortho EIA tests & INNO-LIA immunoblot test
Details
Risk group (please answer all)
Sexual contact with known case
Yes No Unknown
Recipient of blood/blood products
Injecting drug user
Vertical transmission Risk group of mother
Renal dialysis patient
Accidental needlestick/occupational exposure
If other exposure, please specify
Possible sexual exposure (e.g. multiple, new, or high risk partner(s)) Details
Product Year
Recipient of organ or tissue transplant
Tattooing/body piercing (excl. ear lobes)/acupuncture
Please indicate most likely risk group
Surgical or dental procedures Details
Infection likely to have been acquired abroad? Country
Laboratory  Details Test* ResultPositive Negative Indeterminate
Date of first confirmed
HCV positive result
HCV EIA
HCV Immunoblot
HCV PCR
Please circle HCV genotype
(if available) 1 2 3 4 5 6 Further genotyping details
Laboratory
Weak positive
Hepatitis C status at time of notification Acute Chronic Unknown
Newly diagnosed case Case was previously diagnosed, but not notifiedOr
Notification details
Date of completion
Form completed by
SPHM responsible
HCV antibody-antigen
Has the case donated blood recently?
If yes, date of blood donation
Yes No Unknown
Born in endemic country or asylum seeker
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APPENDIX 10 - LABORATORy METHODS FOR HEPATITIS C TESTING
Hepatitis C diagnostics fall into two general categories: serological and molecular investigations.  Serological 
investigations include the detection of hepatitis C antibodies and  more recently the detection  hepatitis C core 
antigen in serum. Serological confirmation of hepatitis C infection can be achieved by using an alternative hepatitis 
C EIA with different assay format or by the use of hepatitis C line immunoassay.  
Molecular investigation includes the  quantitative detection of hepatitis C RNA (viral load) and hepatitis C 
genotype. Nucleic acid testing is an important component of the diagnostic algorithm for confirmation of hepatitis 
C infection and provides critical prognostic information for guiding treatment and measuring response to antiviral 
therapy. Success of hepatitis C treatment is defined as testing negative for hepatitis C RNA six months after 
cessation of therapy, termed a sustained virological response (SVR). The rate of response to therapy is also an 
important predictor of sustained response with a rapid decline in viral load being a strong predictor of treatment 
success. Genotype tests are important clinically as they predict most accurately the chance of antiviral response 
and dictate the duration of therapy, with patients with genotype 2 or 3 more likely to achieve a SVR than genotype 1 
or 4. Current guidelines recommend that:
i. A sensitive nucleic acid test (i.e. low limit of detection of <50 IU hepatitis C RNA/ml) should be used for 
the determination of hepatitis C RNA.
ii. A genotype and quantitative hepatitis C RNA (measured in IU/ml) test should be performed on all patients 
prior to therapy to best assess the probability of response to and to aid selection of an appropriate 
therapeutic regimen.
iii. The same type of quantitative test  should then be used to monitor response to treatment and the 
likelihood of a SVR.
Molecular characterisation of hepatitis C virus at the genotypic level is of significant  epidemiological benefit in 
mapping the evolution of hepatitis C infection within defined risk groups.  More detailed molecular analysis of 
the hepatitis C viral genome in the form of hepatitis C phylogenetic studies requires analysis of a hypervariable 
component of the gene. This type of analysis can be used to establish genetic relationships between cohorts of 
hepatitis C infected patients.
APPENDIX 11 - GENERAL PRACTICE GUIDELINES ON THE MANAGEMENT OF 
HEPATITIS C AMONG DRUG USERS
NB – Guidelines are developed as a guide to the management of patients with a particular condition.  As each 
individual patient may differ in many respects, guidelines should only be applied in this context and in accordance 
with a patient’s wishes.
Screening for hepatitis C
 All people at risk of hepatitis C should be offered testing and any patient with signs or symptoms suggestive of 
hepatitis, or requesting testing should also be tested.
 Pre-test discussion should take place and include
o Information on hepatitis C infection
o The benefits and risks of HCV testing, 
o Reassurance with regard to confidentiality, 
o Education on how to reduce the risk of transmission, 
o Discussion on the risk of co-infection with HIV or hepatitis B (patients at risk for hepatitis C should also 
be offered testing for HIV)
 Post-test discussion should take place and if possible the results should be given in person to the patient by 
the person who undertook the pre-test discussion
 In the case of a negative result repeat testing should be offered if exposure to the virus occurred within the last 
six months
Initial management
 General advice should be given to include
o Advice on reducing the risk of further liver damage
 Patients should be screened for hepatitis B and offered vaccination if non-immune
 Vaccination against hepatitis A should also be recommended
o Information on how hepatitis C is and is not transmitted
o Advice on safe drug use
o Education on how to reduce transmitting the virus to others 
o Advice on sexual relationships and mother-to-infant transmission
 Psychosocial supports available to the patient should be identified and referrals made if necessary to relevant 
agencies / disciplines
 A follow-up appointment should be made
Subsequent management
The following areas should be explored as a guide to predict which patients may or may not benefit from therapy or 
to identify issues that may need to be addressed prior to referral for treatment
 Drug use 
o Non-prescribed opiate 
o Cocaine use 
o Non-therapeutic doses of benzodiazepines or tricyclic antidepressants 
 Alcohol intake above the recommended weekly limits
 Significant concurrent psychiatric morbidity
 Major concurrent social problems
The following information should be provided when referring a patient to a Hepatology or infectious disease service 
for further management
 Results of HCV screening test and if available, subsequent PCR / genotype testing (and a copy of the results)
 Clinical evaluation of liver status
 Results of LFT/FBC
 Contact address or telephone number for correspondence with patient
 Current non-prescription drug use
Additional information that could also be provided includes  
 Results of tests for other bloodborne viruses (including HIV and HBV)
 Details of vaccinations against hepatitis B and A
 Duration of methadone therapy and dose
 Whether or not the potential risks and benefits of treatment have been discussed 
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GLOSSARy OF TERMS
Anti-D
Antibodies against rhesus D antigens. A small amount of the baby’s blood can enter the mother’s circulation 
during pregnancy, or larger amounts can enter during delivery. If the mother is negative for rhesus proteins and the 
baby is rhesus positive, the mother produces antibodies against the rhesus D antigens. These antibodies can pass 
through the placenta and damage the baby. The risk of disease is higher with subsequent pregnancies with rhesus 
positive babies. Anti-D immunoglobulin given during or after pregnancy prevents this.
Cirrhosis
Widespread replacement of liver tissue by fibrotic scar tissue and regenerative nodules, leading to progressive loss 
of liver function.
Fibrosis
Liver fibrosis refers to the accumulation of tough fibrous scar tissue in the liver.
Genotype testing
Hepatitis C genotype tests are used to determine which of the genetically distinct types of hepatitis C virus are 
present in the patient’s blood. Hepatitis C genotype is important in predicting response to anti-viral therapy.
Hepatitis C EIA (Enzyme Immunoassay) /ELISA (Enzyme-Linked Immunosorbent Assay)
An assay that detects antibodies against specific hepatitis C antigens in a patient’s blood. The hepatitis C EIA test 
is usually used as an initial screening test for hepatitis C antibodies.
Hepatocellular carcinoma (HCC)
Primary malignancy (cancer) of the liver.
Liver biopsy
A liver biopsy is a medical procedure involving the removal of a small piece of liver using a special needle.  This is 
then examined under a microscope for signs of liver abnormality.
Liver function tests (LFTs)
Liver function tests are a group of blood tests which provide information about how the patient’s liver is functioning 
and may act as indicators of liver injury.
Nucleic acid is a macromolecule carrying genetic information.  Nucleic acids are universal in living things, as 
they are found in all cells and viruses.   The most common nucleic acids are deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA).  If a test detects nucleic acid then virus is present.
Polymerase Chain Reaction is a technique widely used in molecular biology. It derives its name from one of its key 
components, a DNA polymerase used to amplify a piece of DNA.  PCR can be used to detect viral DNA. The high 
sensitivity of PCR permits virus detection soon after infection and even before the onset of disease. 
Sensitivity
This measures how often a test turns out positive when it is being used on people who have the disease or 
condition.
Specificity
This measures how often a test turns out negative when it is being used on people who do not have the disease or 
condition.
Sustained virological response
The absence of detectable hepatitis C RNA in the serum as shown by a qualitative hepatitis C RNA assay with lower 
limit of detection of 50 IU/ml or less at 24 weeks after the end of treatment.
Viral Load The amount of virus (“viral load”) in a patient can be quantified by using PCR-based DNA quantitation 
techniques
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ABBREVIATIONS USED
Anti-HCV  Antibody to hepatitis C virus
CNS  Clinical Nurse Specialist
CSO  Central Statistics Office
DAHCIG  Dublin Area Hepatitis C Initiative Group
DoHC  Department of Health and Children
DPC  Data Protection Commissioner
DPH  Director of Public Health 
DTCB  Drug Treatment Centre Board
EIA  Enzyme immunoassay, a screening test for hepatitis C
EMGs  Ethnic minority groups
EPP  Exposure-prone procedures
ERHA  Eastern Regional Health Authority 
ESRI  Economic and Social Research Institute
GPSSA  GP specialist in substance abuse
HAA  Health (Amendment) Act
HBsAg  Hepatitis B surface antigen
HCC Hepatocellular Carcinoma
HCLNS  Hepatitis C liaison clinical nurse specialist
HCV  Hepatitis C virus
HIPE  Hospital In-Patient Enquiry System
HIQA  Health Information and Quality Authority
HIV  Human immunodeficiency virus
HPSC  Health Protection Surveillance Centre
HRB  Health Research Board
HSE  Health Service Executive
IBTS  Irish Blood Transfusion Service
ICGP  Irish College of General Practitioners
IDU  Injecting Drug User
IPS  Irish Prison Service
LHO  Local Health Office
MOH  Medical Officer of Health
MQI  Merchant’s Quay Ireland
NACD  National Advisory Committee on Drugs
NCRI  National Cancer Registry of Ireland
NDST  National Drugs Strategy Team
NDTRS  National Drug Treatment Reporting System
NEP  Needle-exchange programme
NPV  Negative predictive value
NVRL  National Virus Reference Laboratory
PCR  Polymerase chain reaction
PMU  Permanent make up
PNEP  Prison-based needle exchange programmes
PPV  Positive predictive value
QALy  Quality-Adjusted Life Year
RIBA  Recombinant immunoblot assay, a more specific hepatitis C test
RNA  Ribonucleic acid
SVR  Sustained virological response
WHO  World Health Organization
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